{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:40:10Z","timestamp":1794627610516,"version":"4.9.1"},"reference-count":363,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Cardiol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1038\/s41569-025-01167-6","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:02:07Z","timestamp":1750532527000},"page":"773-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Mechano-energetic uncoupling in heart failure"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-6727","authenticated-orcid":false,"given":"Dunja","family":"Aksentijevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4419-6821","authenticated-orcid":false,"given":"Simon","family":"Sedej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Fauconnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4912-4915","authenticated-orcid":false,"given":"Melanie","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5042-9054","authenticated-orcid":false,"given":"Mahmoud","family":"Abdellatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5137-7228","authenticated-orcid":false,"given":"Katrin","family":"Streckfuss-B\u00f6meke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Ventura-Clapier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5224-5788","authenticated-orcid":false,"given":"Jolanda","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9140","authenticated-orcid":false,"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Bertero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Dudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9192-7674","authenticated-orcid":false,"given":"Vasco","family":"Sequeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-4559","authenticated-orcid":false,"given":"Christoph","family":"Maack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"1167_CR1","doi-asserted-by":"publisher","unstructured":"Bozkurt, B. et al. HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the Heart Failure Society of America. J. Card. Fail. https:\/\/doi.org\/10.1016\/j.cardfail.2024.07.001 (2024).","DOI":"10.1016\/j.cardfail.2024.07.001"},{"key":"1167_CR2","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","volume":"384","author":"M Ng","year":"2014","unstructured":"Ng, M. et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980\u20132013: a systematic analysis for the global burden of disease study 2013. Lancet 384, 766\u2013781 (2014).","journal-title":"Lancet"},{"key":"1167_CR3","doi-asserted-by":"publisher","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","volume":"39","author":"C Maack","year":"2018","unstructured":"Maack, C. et al. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the translational research committee of the Heart Failure Association\u2013European Society of Cardiology. Eur. Heart J. 39, 4243\u20134254 (2018).","journal-title":"Eur. Heart J."},{"key":"1167_CR4","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","volume":"62","author":"E Braunwald","year":"2019","unstructured":"Braunwald, E. Diabetes, heart failure, and renal dysfunction: the vicious circles. Prog. Cardiovasc. Dis. 62, 298\u2013302 (2019).","journal-title":"Prog. Cardiovasc. Dis."},{"key":"1167_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1161\/CIRCULATIONAHA.119.044056","volume":"141","author":"J Robertson","year":"2020","unstructured":"Robertson, J. et al. Body mass index in young women and risk of cardiomyopathy: a long-term follow-up study in Sweden. Circulation 141, 520\u2013529 (2020).","journal-title":"Circulation"},{"key":"1167_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/CIRCULATIONAHA.118.039132","volume":"140","author":"J Robertson","year":"2019","unstructured":"Robertson, J. et al. Higher body mass index in adolescence predicts cardiomyopathy risk in midlife. Circulation 140, 117\u2013125 (2019).","journal-title":"Circulation"},{"key":"1167_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ahj.2007.01.041","volume":"154","author":"S Setoguchi","year":"2007","unstructured":"Setoguchi, S., Stevenson, L. W. & Schneeweiss, S. Repeated hospitalizations predict mortality in the community population with heart failure. Am. Heart J. 154, 260\u2013266 (2007).","journal-title":"Am. Heart J."},{"key":"1167_CR8","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ejhf.822","volume":"19","author":"MA Mamas","year":"2017","unstructured":"Mamas, M. A. et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur. J. Heart Fail. 19, 1095\u20131104 (2017).","journal-title":"Eur. J. Heart Fail."},{"key":"1167_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1126\/science.abc8861","volume":"370","author":"D Murashige","year":"2020","unstructured":"Murashige, D. et al. Comprehensive quantification of fuel use by the failing and nonfailing human heart. Science 370, 364\u2013368 (2020).","journal-title":"Science"},{"key":"1167_CR10","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1161\/01.CIR.96.7.2190","volume":"96","author":"S Neubauer","year":"1997","unstructured":"Neubauer, S. et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96, 2190\u20132196 (1997).","journal-title":"Circulation"},{"key":"1167_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jacc.2009.05.012","volume":"54","author":"TT Phan","year":"2009","unstructured":"Phan, T. T. et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J. Am. Coll. Cardiol. 54, 402\u2013409 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12968-018-0511-6","volume":"20","author":"M Mahmod","year":"2018","unstructured":"Mahmod, M. et al. The interplay between metabolic alterations, diastolic strain rate and exercise capacity in mild heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study. J. Cardiovasc. Magn. Reson. 20, 88 (2018).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"1167_CR13","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1056\/NEJMra063052","volume":"356","author":"S Neubauer","year":"2007","unstructured":"Neubauer, S. The failing heart \u2014 an engine out of fuel. N. Engl. J. Med. 356, 1140\u20131151 (2007).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41569-018-0044-6","volume":"15","author":"E Bertero","year":"2018","unstructured":"Bertero, E. & Maack, C. Metabolic remodelling in heart failure. Nat. Rev. Cardiol. 15, 457\u2013470 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"1167_CR15","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCRESAHA.118.310082","volume":"122","author":"E Bertero","year":"2018","unstructured":"Bertero, E. & Maack, C. Calcium signaling and reactive oxygen species in mitochondria. Circ. Res. 122, 1460\u20131478 (2018).","journal-title":"Circ. Res."},{"key":"1167_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1093\/eurjhf\/hfr173","volume":"14","author":"H Ardehali","year":"2012","unstructured":"Ardehali, H. et al. Targeting myocardial substrate metabolism in heart failure: potential for new therapies. Eur. J. Heart Fail. 14, 120\u2013129 (2012).","journal-title":"Eur. J. Heart Fail."},{"key":"1167_CR17","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection fraction. N. Engl. J. Med. 385, 1451\u20131461 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR18","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 381, 1995\u20132008 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR19","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N. Engl. J. Med. 383, 1413\u20131424 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon, S. D. et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N. Engl. J. Med. 387, 1089\u20131098 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod, M. N. et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet 404, 949\u2013961 (2024).","journal-title":"Lancet"},{"key":"1167_CR22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer, M. et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 392, 427\u2013437 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069\u20131084 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR24","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N. Engl. J. Med. 390, 1394\u20131407 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR25","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/eurheartj\/ehaa281","volume":"41","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm, M., Bewarder, Y. & Kindermann, I. Ejection fraction in heart failure revisited- where does the evidence start? Eur. Heart J. 41, 2363\u20132365 (2020).","journal-title":"Eur. Heart J."},{"key":"1167_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink, J. R. et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N. Engl. J. Med. 384, 105\u2013116 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto, I. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396, 759\u2013769 (2020).","journal-title":"Lancet"},{"key":"1167_CR28","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","volume":"390","author":"MS Maron","year":"2024","unstructured":"Maron, M. S. et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N. Engl. J. Med. 390, 1849\u20131861 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41569-022-00682-0","volume":"19","author":"SJ Lehman","year":"2022","unstructured":"Lehman, S. J., Crocini, C. & Leinwand, L. A. Targeting the sarcomere in inherited cardiomyopathies. Nat. Rev. Cardiol. 19, 353\u2013363 (2022).","journal-title":"Nat. Rev. Cardiol."},{"key":"1167_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1113\/jphysiol.2005.101444","volume":"571","author":"V Saks","year":"2006","unstructured":"Saks, V. et al. Cardiac system bioenergetics: metabolic basis of the Frank\u2013Starling law. J. Physiol. 571, 253\u2013273 (2006).","journal-title":"J. Physiol."},{"key":"1167_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/415198a","volume":"415","author":"DM Bers","year":"2002","unstructured":"Bers, D. M. Cardiac excitation-contraction coupling. Nature 415, 198\u2013205 (2002).","journal-title":"Nature"},{"key":"1167_CR32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1113\/jphysiol.1994.sp020471","volume":"481","author":"M Schramm","year":"1994","unstructured":"Schramm, M., Klieber, H. G. & Daut, J. The energy expenditure of actomyosin-ATPase, Ca(2+)-ATPase and Na+,K(+)-ATPase in guinea-pig cardiac ventricular muscle. J. Physiol. 481, 647\u2013662 (1994).","journal-title":"J. Physiol."},{"key":"1167_CR33","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cell.2005.02.001","volume":"120","author":"RS Balaban","year":"2005","unstructured":"Balaban, R. S., Nemoto, S. & Finkel, T. Mitochondria, oxidants, and aging. Cell 120, 483\u2013495 (2005).","journal-title":"Cell"},{"key":"1167_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.yjmcc.2014.03.011","volume":"73C","author":"A Nickel","year":"2014","unstructured":"Nickel, A., Kohlhaas, M. & Maack, C. Mitochondrial reactive oxygen species production and elimination. J. Mol. Cell. Cardiol. 73C, 26\u201333 (2014).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbabio.2010.02.016","volume":"1797","author":"MA Aon","year":"2010","unstructured":"Aon, M. A., Cortassa, S. & O\u2019Rourke, B. Redox-optimized ROS balance: a unifying hypothesis. Biochim. Biophys. Acta 1797, 865\u2013877 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"1167_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.bbabio.2013.11.007","volume":"1837","author":"S Cortassa","year":"2014","unstructured":"Cortassa, S., O\u2019Rourke, B. & Aon, M. A. Redox-optimized ROS balance and the relationship between mitochondrial respiration and ROS. Biochim. Biophys. Acta 1837, 287\u2013295 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"1167_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1152\/advan.00072.2011","volume":"37","author":"JL Puglisi","year":"2013","unstructured":"Puglisi, J. L., Negroni, J. A., Chen-Izu, Y. & Bers, D. M. The force\u2013frequency relationship: insights from mathematical modeling. Adv. Physiol. Educ. 37, 28\u201334 (2013).","journal-title":"Adv. Physiol. Educ."},{"key":"1167_CR38","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1093\/eurheartj\/ehy600","volume":"40","author":"C Maack","year":"2019","unstructured":"Maack, C. et al. Treatments targeting inotropy. Eur. Heart J. 40, 3626\u20133644 (2019).","journal-title":"Eur. Heart J."},{"key":"1167_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12551-020-00615-6","volume":"12","author":"S Kaur","year":"2020","unstructured":"Kaur, S., Shen, X., Power, A. & Ward, M. L. Stretch modulation of cardiac contractility: importance of myocyte calcium during the slow force response. Biophys. Rev. 12, 135\u2013142 (2020).","journal-title":"Biophys. Rev."},{"key":"1167_CR40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/CIRCRESAHA.123.323173","volume":"134","author":"V Sequeira","year":"2024","unstructured":"Sequeira, V., Maack, C., Reil, G. H. & Reil, J. C. Exploring the connection between relaxed myosin states and the anrep effect. Circ. Res. 134, 117\u2013134 (2024).","journal-title":"Circ. Res."},{"key":"1167_CR41","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev-physiol-022724-104846","volume":"87","author":"Y Chen-Izu","year":"2025","unstructured":"Chen-Izu, Y., Banyasz, T., Shaw, J. A. & Izu, L. T. The heart is a smart pump: mechanotransduction mechanisms of the frank-starling law and the anrep effect. Annu. Rev. Physiol. 87, 53\u201377 (2025).","journal-title":"Annu. Rev. Physiol."},{"key":"1167_CR42","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/01.RES.80.1.82","volume":"80","author":"R Brandes","year":"1997","unstructured":"Brandes, R. & Bers, D. M. Intracellular Ca2+ increases the mitochondrial NADH concentration during elevated work in intact cardiac muscle. Circ. Res. 80, 82\u201387 (1997).","journal-title":"Circ. Res."},{"key":"1167_CR43","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1016\/S0006-3495(03)75079-6","volume":"84","author":"S Cortassa","year":"2003","unstructured":"Cortassa, S., Aon, M. A., Marb\u00e1n, E., Winslow, R. L. & O\u2019Rourke, B. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys. J. 84, 2734\u20132755 (2003).","journal-title":"Biophys. J."},{"key":"1167_CR44","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1161\/01.RES.0000232546.92777.05","volume":"99","author":"C Maack","year":"2006","unstructured":"Maack, C. et al. Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation\u2013contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ. Res. 99, 172\u2013182 (2006).","journal-title":"Circ. Res."},{"key":"1167_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s00395-007-0666-z","volume":"102","author":"C Maack","year":"2007","unstructured":"Maack, C. & O\u2019Rourke, B. Excitation\u2013contraction coupling and mitochondrial energetics. Basic Res. Cardiol. 102, 369\u2013392 (2007).","journal-title":"Basic Res. Cardiol."},{"key":"1167_CR46","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1152\/physrev.1990.70.2.391","volume":"70","author":"JG McCormack","year":"1990","unstructured":"McCormack, J. G., Halestrap, A. P. & Denton, R. M. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol. Rev. 70, 391\u2013425 (1990).","journal-title":"Physiol. Rev."},{"key":"1167_CR47","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1074\/jbc.M002923200","volume":"276","author":"PR Territo","year":"2001","unstructured":"Territo, P. R., French, S. A., Dunleavy, M. C., Evans, F. J. & Balaban, R. S. Calcium activation of heart mitochondrial oxidative phosphorylation: rapid kinetics of mVO2, NADH, and light scattering. J. Biol. Chem. 276, 2586\u20132599 (2001).","journal-title":"J. Biol. Chem."},{"key":"1167_CR48","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1006\/jmcc.2002.2082","volume":"34","author":"RS Balaban","year":"2002","unstructured":"Balaban, R. S. Cardiac energy metabolism homeostasis: role of cytosolic calcium. J. Mol. Cell. Cardiol. 34, 1259\u20131271 (2002).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.celrep.2015.06.017","volume":"12","author":"TS Luongo","year":"2015","unstructured":"Luongo, T. S. et al. The mitochondrial calcium uniporter matches energetic supply with cardiac workload during stress and modulates permeability transition. Cell Rep. 12, 23\u201334 (2015).","journal-title":"Cell Rep."},{"key":"1167_CR50","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIRCULATIONAHA.109.914911","volume":"121","author":"M Kohlhaas","year":"2010","unstructured":"Kohlhaas, M. et al. Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation 121, 1606\u20131613 (2010).","journal-title":"Circulation"},{"key":"1167_CR51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1152\/physrev.00004.2005","volume":"86","author":"R Rizzuto","year":"2006","unstructured":"Rizzuto, R. & Pozzan, T. Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol. Rev. 86, 369\u2013408 (2006).","journal-title":"Physiol. Rev."},{"key":"1167_CR52","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/CIRCRESAHA.111.300501","volume":"112","author":"X Lu","year":"2013","unstructured":"Lu, X. et al. Measuring local gradients of intramitochondrial [Ca2+] in cardiac myocytes during sarcoplasmic reticulum Ca(2+) release. Circ. Res. 112, 424\u2013431 (2013).","journal-title":"Circ. Res."},{"key":"1167_CR53","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1161\/CIRCULATIONAHA.110.968057","volume":"122","author":"M Kohlhaas","year":"2010","unstructured":"Kohlhaas, M. & Maack, C. Adverse bioenergetic consequences of Na+\u2013Ca2+ exchanger-mediated Ca2+ influx in cardiac myocytes. Circulation 122, 2273\u20132280 (2010).","journal-title":"Circulation"},{"key":"1167_CR54","doi-asserted-by":"publisher","first-page":"10479","DOI":"10.1073\/pnas.1300410110","volume":"110","author":"GS Williams","year":"2013","unstructured":"Williams, G. S., Boyman, L., Chikando, A. C., Khairallah, R. J. & Lederer, W. J. Mitochondrial calcium uptake. Proc. Natl Acad. Sci. USA 110, 10479\u201310486 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR55","doi-asserted-by":"publisher","first-page":"6327","DOI":"10.1242\/jcs.01559","volume":"117","author":"L Mackenzie","year":"2004","unstructured":"Mackenzie, L., Roderick, H. L., Berridge, M. J., Conway, S. J. & Bootman, M. D. The spatial pattern of atrial cardiomyocyte calcium signalling modulates contraction. J. Cell Sci. 117, 6327\u20136337 (2004).","journal-title":"J. Cell Sci."},{"key":"1167_CR56","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1161\/CIRCULATIONAHA.114.008927","volume":"130","author":"S Ljubojevic","year":"2014","unstructured":"Ljubojevic, S. et al. Early remodeling of perinuclear Ca2+ stores and nucleoplasmic Ca2+ signaling during the development of hypertrophy and heart failure. Circulation 130, 244\u2013255 (2014).","journal-title":"Circulation"},{"key":"1167_CR57","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2021.0320","volume":"377","author":"J Voglhuber","year":"2022","unstructured":"Voglhuber, J. et al. Functional remodelling of perinuclear mitochondria alters nucleoplasmic Ca2+ signalling in heart failure. Philos. Trans. R. Soc. Lond. B 377, 20210320 (2022).","journal-title":"Philos. Trans. R. Soc. Lond. B"},{"key":"1167_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2021.102355","volume":"95","author":"WM Rosencrans","year":"2021","unstructured":"Rosencrans, W. M., Aguilella, V. M., Rostovtseva, T. K. & Bezrukov, S. M. \u03b1-Synuclein emerges as a potent regulator of VDAC-facilitated calcium transport. Cell Calcium 95, 102355 (2021).","journal-title":"Cell Calcium"},{"key":"1167_CR59","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41586-018-0331-8","volume":"559","author":"R Baradaran","year":"2018","unstructured":"Baradaran, R., Wang, C., Siliciano, A. F. & Long, S. B. Cryo-EM structures of fungal and metazoan mitochondrial calcium uniporters. Nature 559, 580\u2013584 (2018).","journal-title":"Nature"},{"key":"1167_CR60","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature10234","volume":"476","author":"JM Baughman","year":"2011","unstructured":"Baughman, J. M. et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 476, 341\u2013345 (2011).","journal-title":"Nature"},{"key":"1167_CR61","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1126\/science.1214977","volume":"336","author":"AG Bick","year":"2012","unstructured":"Bick, A. G., Calvo, S. E. & Mootha, V. K. Evolutionary diversity of the mitochondrial calcium uniporter. Science 336, 886 (2012).","journal-title":"Science"},{"key":"1167_CR62","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature10230","volume":"476","author":"D De Stefani","year":"2011","unstructured":"De Stefani, D., Raffaello, A., Teardo, E., Szabo, I. & Rizzuto, R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 476, 336\u2013340 (2011).","journal-title":"Nature"},{"key":"1167_CR63","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.1242993","volume":"342","author":"Y Sancak","year":"2013","unstructured":"Sancak, Y. et al. EMRE is an essential component of the mitochondrial calcium uniporter complex. Science 342, 1379\u20131382 (2013).","journal-title":"Science"},{"key":"1167_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101037","volume":"23","author":"R Payne","year":"2020","unstructured":"Payne, R., Li, C. & Foskett, J. K. Variable assembly of EMRE and MCU creates functional channels with distinct gatekeeping profiles. iScience 23, 101037 (2020).","journal-title":"iScience"},{"key":"1167_CR65","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/2211-5463.13371","volume":"12","author":"A Watanabe","year":"2022","unstructured":"Watanabe, A. et al. Quantitative analysis of mitochondrial calcium uniporter (MCU) and essential MCU regulator (EMRE) in mitochondria from mouse tissues and HeLa cells. FEBS Open Bio 12, 811\u2013826 (2022).","journal-title":"FEBS Open Bio"},{"key":"1167_CR66","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nature09358","volume":"467","author":"F Perocchi","year":"2010","unstructured":"Perocchi, F. et al. MICU1 encodes a mitochondrial EF hand protein required for Ca2+ uptake. Nature 467, 291\u2013296 (2010).","journal-title":"Nature"},{"key":"1167_CR67","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.cmet.2013.04.020","volume":"17","author":"G Csordas","year":"2013","unstructured":"Csordas, G. et al. MICU1 controls both the threshold and cooperative activation of the mitochondrial Ca2+ uniporter. Cell Metab. 17, 976\u2013987 (2013).","journal-title":"Cell Metab."},{"key":"1167_CR68","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1016\/j.molcel.2022.09.006","volume":"82","author":"CW Tsai","year":"2022","unstructured":"Tsai, C. W. et al. Mechanisms and significance of tissue-specific MICU regulation of the mitochondrial calcium uniporter complex. Mol. Cell 82, 3661\u20133676 e3668 (2022).","journal-title":"Mol. Cell"},{"key":"1167_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055785","volume":"8","author":"M Plovanich","year":"2013","unstructured":"Plovanich, M. et al. MICU2, a paralog of MICU1, resides within the mitochondrial uniporter complex to regulate calcium handling. PLoS ONE 8, e55785 (2013).","journal-title":"PLoS ONE"},{"key":"1167_CR70","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41418-018-0113-8","volume":"26","author":"M Patron","year":"2019","unstructured":"Patron, M., Granatiero, V., Espino, J., Rizzuto, R. & De Stefani, D. MICU3 is a tissue-specific enhancer of mitochondrial calcium uptake. Cell Death Differ. 26, 179\u2013195 (2019).","journal-title":"Cell Death Differ."},{"key":"1167_CR71","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1073\/pnas.1817759116","volume":"116","author":"KJ Kamer","year":"2019","unstructured":"Kamer, K. J., Jiang, W., Kaushik, V. K., Mootha, V. K. & Grabarek, Z. Crystal structure of MICU2 and comparison with MICU1 reveal insights into the uniporter gating mechanism. Proc. Natl Acad. Sci. USA 116, 3546\u20133555 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR72","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.celrep.2017.02.032","volume":"18","author":"M Paillard","year":"2017","unstructured":"Paillard, M. et al. Tissue-specific mitochondrial decoding of cytoplasmic Ca2+ signals is controlled by the stoichiometry of MICU1\/2 and MCU. Cell Rep. 18, 2291\u20132300 (2017).","journal-title":"Cell Rep."},{"key":"1167_CR73","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.molcel.2014.01.013","volume":"53","author":"M Patron","year":"2014","unstructured":"Patron, M. et al. MICU1 and MICU2 finely tune the mitochondrial Ca2+ uniporter by exerting opposite effects on MCU activity. Mol. Cell 53, 726\u2013737 (2014).","journal-title":"Mol. Cell"},{"key":"1167_CR74","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.celrep.2019.01.022","volume":"26","author":"Y Xing","year":"2019","unstructured":"Xing, Y. et al. Dimerization of MICU proteins controls Ca2+ influx through the mitochondrial Ca2+ uniporter. Cell Rep. 26, 1203\u20131212 e1204 (2019).","journal-title":"Cell Rep."},{"key":"1167_CR75","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1161\/CIRCULATIONAHA.118.037968","volume":"140","author":"JP Lambert","year":"2019","unstructured":"Lambert, J. P. et al. MCUB regulates the molecular composition of the mitochondrial calcium uniporter channel to limit mitochondrial calcium overload during stress. Circulation 140, 1720\u20131733 (2019).","journal-title":"Circulation"},{"key":"1167_CR76","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1038\/emboj.2013.157","volume":"32","author":"A Raffaello","year":"2013","unstructured":"Raffaello, A. et al. The mitochondrial calcium uniporter is a multimer that can include a dominant-negative pore-forming subunit. EMBO J. 32, 2362\u20132376 (2013).","journal-title":"EMBO J."},{"key":"1167_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2325","volume":"3","author":"F Fieni","year":"2012","unstructured":"Fieni, F., Lee, S. B., Jan, Y. N. & Kirichok, Y. Activity of the mitochondrial calcium uniporter varies greatly between tissues. Nat. Commun. 3, 1317 (2012).","journal-title":"Nat. Commun."},{"key":"1167_CR78","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1042\/bst0310930","volume":"31","author":"MJ Berridge","year":"2003","unstructured":"Berridge, M. J. Cardiac calcium signalling. Biochem. Soc. Trans. 31, 930\u2013933 (2003).","journal-title":"Biochem. Soc. Trans."},{"key":"1167_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2020.102288","volume":"92","author":"D Tomar","year":"2020","unstructured":"Tomar, D. & Elrod, J. W. Metabolite regulation of the mitochondrial calcium uniporter channel. Cell Calcium 92, 102288 (2020).","journal-title":"Cell Calcium"},{"key":"1167_CR80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.celrep.2015.06.002","volume":"12","author":"JQ Kwong","year":"2015","unstructured":"Kwong, J. Q. et al. The mitochondrial calcium uniporter selectively matches metabolic output to acute contractile stress in the heart. Cell Rep. 12, 15\u201322 (2015).","journal-title":"Cell Rep."},{"key":"1167_CR81","doi-asserted-by":"publisher","first-page":"C755","DOI":"10.1152\/ajpcell.1990.258.5.C755","volume":"258","author":"TE Gunter","year":"1990","unstructured":"Gunter, T. E. & Pfeiffer, D. R. Mechanisms by which mitochondria transport calcium. Am. J. Physiol. 258, C755\u2013C786 (1990).","journal-title":"Am. J. Physiol."},{"key":"1167_CR82","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature02246","volume":"427","author":"Y Kirichok","year":"2004","unstructured":"Kirichok, Y., Krapivinsky, G. & Clapham, D. E. The mitochondrial calcium uniporter is a highly selective ion channel. Nature 427, 360\u2013364 (2004).","journal-title":"Nature"},{"key":"1167_CR83","doi-asserted-by":"publisher","first-page":"23343","DOI":"10.1074\/jbc.M116.755496","volume":"291","author":"S De La Fuente","year":"2016","unstructured":"De La Fuente, S. et al. Strategic positioning and biased activity of the mitochondrial calcium uniporter in cardiac muscle. J. Biol. Chem. 291, 23343\u201323362 (2016).","journal-title":"J. Biol. Chem."},{"key":"1167_CR84","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/cvr\/cvt032","volume":"98","author":"M Kohlhaas","year":"2013","unstructured":"Kohlhaas, M. & Maack, C. Calcium release microdomains and mitochondria. Cardiovasc. Res. 98, 259\u2013268 (2013).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR85","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/cdd.2016.52","volume":"23","author":"M Giacomello","year":"2016","unstructured":"Giacomello, M. & Pellegrini, L. The coming of age of the mitochondria\u2013ER contact: a matter of thickness. Cell Death Differ. 23, 1417\u20131427 (2016).","journal-title":"Cell Death Differ."},{"key":"1167_CR86","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0006-3495(98)77776-8","volume":"74","author":"A Peskoff","year":"1998","unstructured":"Peskoff, A. & Langer, G. A. Calcium concentration and movement in the ventricular cardiac cell during an excitation\u2013contraction cycle. Biophys. J. 74, 153\u2013174 (1998).","journal-title":"Biophys. J."},{"key":"1167_CR87","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/cvr\/cvw185","volume":"112","author":"LK Seidlmayer","year":"2016","unstructured":"Seidlmayer, L. K. et al. Inositol 1,4,5-trisphosphate-mediated sarcoplasmic reticulum-mitochondrial crosstalk influences adenosine triphosphate production via mitochondrial Ca2+ uptake through the mitochondrial ryanodine receptor in cardiac myocytes. Cardiovasc. Res. 112, 491\u2013501 (2016).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR88","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1161\/CIRCULATIONAHA.117.030235","volume":"136","author":"S Wu","year":"2017","unstructured":"Wu, S. et al. Binding of FUN14 domain containing 1 with inositol 1,4,5-trisphosphate receptor in mitochondria-associated endoplasmic reticulum membranes maintains mitochondrial dynamics and function in hearts in vivo. Circulation 136, 2248\u20132266 (2017).","journal-title":"Circulation"},{"key":"1167_CR89","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1161\/CIRCRESAHA.112.266585","volume":"111","author":"Y Chen","year":"2012","unstructured":"Chen, Y. et al. Mitofusin 2-containing mitochondrial-reticular microdomains direct rapid cardiomyocyte bioenergetic responses via interorganelle Ca2+ crosstalk. Circ. Res. 111, 863\u2013875 (2012).","journal-title":"Circ. Res."},{"key":"1167_CR90","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.yjmcc.2021.08.003","volume":"161","author":"D Aksentijevic","year":"2021","unstructured":"Aksentijevic, D. & Shattock, M. J. With a grain of salt: sodium elevation and metabolic remodelling in heart failure. J. Mol. Cell. Cardiol. 161, 106\u2013115 (2021).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR91","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1042\/BST20170508","volume":"46","author":"D Aksentijevic","year":"2018","unstructured":"Aksentijevic, D., O\u2019Brien, B. A., Eykyn, T. R. & Shattock, M. J. Is there a causal link between intracellular Na elevation and metabolic remodelling in cardiac hypertrophy? Biochem. Soc. Trans. 46, 817\u2013827 (2018).","journal-title":"Biochem. Soc. Trans."},{"key":"1167_CR92","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S0008-6363(02)00841-6","volume":"57","author":"B Pieske","year":"2003","unstructured":"Pieske, B. & Houser, S. R. [Na+]i handling in the failing human heart. Cardiovasc. Res. 57, 874\u2013886 (2003).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR93","doi-asserted-by":"publisher","first-page":"C813","DOI":"10.1152\/ajpcell.1989.256.4.C813","volume":"256","author":"MJ Shattock","year":"1989","unstructured":"Shattock, M. J. & Bers, D. M. Rat vs. rabbit ventricle: Ca flux and intracellular Na assessed by ion-selective microelectrodes. Am. J. Physiol. 256, C813\u2013C822 (1989).","journal-title":"Am. J. Physiol."},{"key":"1167_CR94","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s00018-012-1134-y","volume":"70","author":"W Fuller","year":"2013","unstructured":"Fuller, W. et al. Regulation of the cardiac sodium pump. Cell Mol. Life Sci. 70, 1357\u20131380 (2013).","journal-title":"Cell Mol. Life Sci."},{"key":"1167_CR95","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1002\/mrm.1910340505","volume":"34","author":"HR Cross","year":"1995","unstructured":"Cross, H. R., Radda, G. K. & Clarke, K. The role of Na+\/K+ ATPase activity during low flow ischemia in preventing myocardial injury: a 31P, 23Na and 87Rb NMR spectroscopic study. Magn. Reson. Med. 34, 673\u2013685 (1995).","journal-title":"Magn. Reson. Med."},{"key":"1167_CR96","doi-asserted-by":"publisher","first-page":"E479","DOI":"10.1152\/ajpendo.2001.281.3.E479","volume":"281","author":"K Okamoto","year":"2001","unstructured":"Okamoto, K., Wang, W., Rounds, J., Chambers, E. A. & Jacobs, D. O. ATP from glycolysis is required for normal sodium homeostasis in resting fast-twitch rodent skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 281, E479\u2013E488 (2001).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1167_CR97","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1161\/CIRCHEARTFAILURE.109.885301","volume":"2","author":"JS Ingwall","year":"2009","unstructured":"Ingwall, J. S. On the control of metabolic remodeling in mitochondria of the failing heart. Circ. Heart Fail. 2, 275\u2013277 (2009).","journal-title":"Circ. Heart Fail."},{"key":"1167_CR98","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1146\/annurev.bi.54.070185.004151","volume":"54","author":"SP Bessman","year":"1985","unstructured":"Bessman, S. P. & Carpenter, C. L. The creatine\u2013creatine phosphate energy shuttle. Annu. Rev. Biochem. 54, 831\u2013862 (1985).","journal-title":"Annu. Rev. Biochem."},{"key":"1167_CR99","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1042\/CS20230616","volume":"138","author":"CA Lygate","year":"2024","unstructured":"Lygate, C. A. Maintaining energy provision in the heart: the creatine kinase system in ischaemia\u2013reperfusion injury and chronic heart failure. Clin. Sci. 138, 491\u2013514 (2024).","journal-title":"Clin. Sci."},{"key":"1167_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2020.103908","volume":"123","author":"C Winkler","year":"2020","unstructured":"Winkler, C. et al. Estimation of left ventricular stroke work based on a large cohort of healthy children. Comput. Biol. Med. 123, 103908 (2020).","journal-title":"Comput. Biol. Med."},{"key":"1167_CR101","doi-asserted-by":"crossref","unstructured":"Lygate, C. A. & Neubauer, S. in Cardiac Energy Metabolism in Health and Disease (eds G. D. Lopaschuk & N. S. Dhalla) 155\u2013168 (Springer, 2014).","DOI":"10.1007\/978-1-4939-1227-8_10"},{"key":"1167_CR102","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/ijms10041729","volume":"10","author":"P Dzeja","year":"2009","unstructured":"Dzeja, P. & Terzic, A. Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int. J. Mol. Sci. 10, 1729\u20131772 (2009).","journal-title":"Int. J. Mol. Sci."},{"key":"1167_CR103","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1152\/physiol.00019.2006","volume":"21","author":"DM Bers","year":"2006","unstructured":"Bers, D. M. Altered cardiac myocyte Ca regulation in heart failure. Physiology 21, 380\u2013387 (2006).","journal-title":"Physiology"},{"key":"1167_CR104","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1161\/01.RES.84.5.562","volume":"84","author":"B O\u2019Rourke","year":"1999","unstructured":"O\u2019Rourke, B. et al. Mechanisms of altered excitation\u2013contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ. Res. 84, 562\u2013570 (1999).","journal-title":"Circ. Res."},{"key":"1167_CR105","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/01.CIR.98.23.2545","volume":"98","author":"VA Maltsev","year":"1998","unstructured":"Maltsev, V. A. et al. Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 98, 2545\u20132552 (1998).","journal-title":"Circulation"},{"key":"1167_CR106","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1161\/01.CIR.0000016701.85760.97","volume":"105","author":"S Despa","year":"2002","unstructured":"Despa, S., Islam, M. A., Weber, C. R., Pogwizd, S. M. & Bers, D. M. Intracellular Na+ concentration is elevated in heart failure but Na\/K pump function is unchanged. Circulation 105, 2543\u20132548 (2002).","journal-title":"Circulation"},{"key":"1167_CR107","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0735-1097(00)00730-0","volume":"36","author":"H Yokoyama","year":"2000","unstructured":"Yokoyama, H., Gunasegaram, S., Harding, S. E. & Avkiran, M. Sarcolemmal Na+\/H+ exchanger activity and expression in human ventricular myocardium. J. Am. Coll. Cardiol. 36, 534\u2013540 (2000).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR108","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0008-6363(02)00809-X","volume":"57","author":"A Baartscheer","year":"2003","unstructured":"Baartscheer, A. et al. Increased Na+\/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc. Res. 57, 1015\u20131024 (2003).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR109","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.yjmcc.2013.05.010","volume":"61","author":"J Bay","year":"2013","unstructured":"Bay, J., Kohlhaas, M. & Maack, C. Intracellular Na+ and cardiac metabolism. J. Mol. Cell. Cardiol. 61, 20\u201327 (2013).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR110","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1161\/01.RES.0000080932.98903.D8","volume":"93","author":"AA Armoundas","year":"2003","unstructured":"Armoundas, A. A., Hobai, I. A., Tomaselli, G. F., Winslow, R. L. & O\u2019Rourke, B. Role of sodium\u2013calcium exchanger in modulating the action potential of ventricular myocytes from normal and failing hearts. Circ. Res. 93, 46\u201353 (2003).","journal-title":"Circ. Res."},{"key":"1167_CR111","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1161\/01.CIR.0000095274.72486.94","volume":"108","author":"CR Weber","year":"2003","unstructured":"Weber, C. R., Piacentino, V. 3rd, Houser, S. R. & Bers, D. M. Dynamic regulation of sodium\/calcium exchange function in human heart failure. Circulation 108, 2224\u20132229 (2003).","journal-title":"Circulation"},{"key":"1167_CR112","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/S0008-6363(02)00732-0","volume":"57","author":"J Weisser-Thomas","year":"2003","unstructured":"Weisser-Thomas, J., Piacentino, V. 3rd, Gaughan, J. P., Margulies, K. & Houser, S. R. Calcium entry via Na\/Ca exchange during the action potential directly contributes to contraction of failing human ventricular myocytes. Cardiovasc. Res. 57, 974\u2013985 (2003).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR113","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1161\/01.RES.81.6.1034","volume":"81","author":"KR Sipido","year":"1997","unstructured":"Sipido, K. R., Maes, M. & Van de Werf, F. Low efficiency of Ca2+ entry through the Na+\u2013Ca2+ exchanger as trigger for Ca2+ release from the sarcoplasmic reticulum. A comparison between L-type Ca2+ current and reverse-mode Na+\u2013Ca2+ exchange. Circ. Res. 81, 1034\u20131044 (1997).","journal-title":"Circ. Res."},{"key":"1167_CR114","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1161\/CIRCULATIONAHA.108.835389","volume":"119","author":"G Michels","year":"2009","unstructured":"Michels, G. et al. Regulation of the human cardiac mitochondrial Ca2+ uptake by 2 different voltage-gated Ca2+ channels. Circulation 119, 2435\u20132443 (2009).","journal-title":"Circulation"},{"key":"1167_CR115","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature22082","volume":"545","author":"TS Luongo","year":"2017","unstructured":"Luongo, T. S. et al. The mitochondrial Na+\/Ca2+ exchanger is essential for Ca2+ homeostasis and viability. Nature 545, 93\u201397 (2017).","journal-title":"Nature"},{"key":"1167_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceca.2022.102618","volume":"105","author":"M Paillard","year":"2022","unstructured":"Paillard, M. et al. Altered composition of the mitochondrial Ca2+uniporter in the failing human heart. Cell Calcium 105, 102618 (2022).","journal-title":"Cell Calcium"},{"key":"1167_CR117","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1161\/CIRCRESAHA.113.301348","volume":"113","author":"C Pinali","year":"2013","unstructured":"Pinali, C., Bennett, H., Davenport, J. B., Trafford, A. W. & Kitmitto, A. Three-dimensional reconstruction of cardiac sarcoplasmic reticulum reveals a continuous network linking transverse-tubules: this organization is perturbed in heart failure. Circ. Res. 113, 1219\u20131230 (2013).","journal-title":"Circ. Res."},{"key":"1167_CR118","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/cvr\/cvv230","volume":"109","author":"KY Goh","year":"2016","unstructured":"Goh, K. Y. et al. Impaired mitochondrial network excitability in failing guinea-pig cardiomyocytes. Cardiovasc. Res. 109, 79\u201389 (2016).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR119","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/cvr\/cvv262","volume":"109","author":"C Maack","year":"2016","unstructured":"Maack, C. Orphaned mitochondria in heart failure. Cardiovasc. Res. 109, 6\u20138 (2016).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR120","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1126\/science.1231031","volume":"340","author":"Y Chen","year":"2013","unstructured":"Chen, Y. & Dorn, G. W. 2nd. PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria. Science 340, 471\u2013475 (2013).","journal-title":"Science"},{"key":"1167_CR121","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2203499119","volume":"119","author":"V Van Steenbergen","year":"2022","unstructured":"Van Steenbergen, V. et al. Nano-positioning and tubulin conformation contribute to axonal transport regulation of mitochondria along microtubules. Proc. Natl Acad. Sci. USA 119, e2203499119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR122","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41591-018-0046-2","volume":"24","author":"CY Chen","year":"2018","unstructured":"Chen, C. Y. et al. Suppression of detyrosinated microtubules improves cardiomyocyte function in human heart failure. Nat. Med. 24, 1225\u20131233 (2018).","journal-title":"Nat. Med."},{"key":"1167_CR123","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.bbabio.2006.03.014","volume":"1757","author":"AV Kuznetsov","year":"2006","unstructured":"Kuznetsov, A. V. et al. Mitochondrial subpopulations and heterogeneity revealed by confocal imaging: possible physiological role? Biochim. Biophys. Acta 1757, 686\u2013691 (2006).","journal-title":"Biochim. Biophys. Acta"},{"key":"1167_CR124","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1006\/jmcc.1998.0706","volume":"30","author":"M Meyer","year":"1998","unstructured":"Meyer, M. et al. Frequency-dependence of myocardial energetics in failing human myocardium as quantified by a new method for the measurement of oxygen consumption in muscle strip preparations. J. Mol. Cell. Cardiol. 30, 1459\u20131470 (1998).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR125","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1161\/CIRCRESAHA.108.175919","volume":"103","author":"T Liu","year":"2008","unstructured":"Liu, T. & O\u2019Rourke, B. Enhancing mitochondrial Ca2+ uptake in myocytes from failing hearts restores energy supply and demand matching. Circ. Res. 103, 279\u2013288 (2008).","journal-title":"Circ. Res."},{"key":"1167_CR126","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2008.02.048","volume":"133","author":"JR Erickson","year":"2008","unstructured":"Erickson, J. R. et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133, 462\u2013474 (2008).","journal-title":"Cell"},{"key":"1167_CR127","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.cell.2008.04.041","volume":"133","author":"T Ago","year":"2008","unstructured":"Ago, T. et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133, 978\u2013993 (2008).","journal-title":"Cell"},{"key":"1167_CR128","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.freeradbiomed.2021.05.013","volume":"171","author":"D Weissman","year":"2021","unstructured":"Weissman, D. & Maack, C. Redox signaling in heart failure and therapeutic implications. Free Radic. Biol. Med. 171, 345\u2013364 (2021).","journal-title":"Free Radic. Biol. Med."},{"key":"1167_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18160-x","volume":"11","author":"D Aksentijevic","year":"2020","unstructured":"Aksentijevic, D. et al. Intracellular sodium elevation reprograms cardiac metabolism. Nat. Commun. 11, 4337 (2020).","journal-title":"Nat. Commun."},{"key":"1167_CR130","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48474-z","volume":"15","author":"YJ Chung","year":"2024","unstructured":"Chung, Y. J. et al. Elevated Na is a dynamic and reversible modulator of mitochondrial metabolism in the heart. Nat. Commun. 15, 4277 (2024).","journal-title":"Nat. Commun."},{"key":"1167_CR131","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.yjmcc.2010.06.012","volume":"49","author":"T Liu","year":"2010","unstructured":"Liu, T., Brown, D. A. & O\u2019Rourke, B. Role of mitochondrial dysfunction in cardiac glycoside toxicity. J. Mol. Cell. Cardiol. 49, 728\u2013736 (2010).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR132","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41586-020-2551-y","volume":"586","author":"P Hernansanz-Agust\u00edn","year":"2020","unstructured":"Hernansanz-Agust\u00edn, P. et al. Na+ controls hypoxic signalling by the mitochondrial respiratory chain. Nature 586, 287\u2013291 (2020).","journal-title":"Nature"},{"key":"1167_CR133","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/CIRCRESAHA.115.303062","volume":"115","author":"T Liu","year":"2014","unstructured":"Liu, T. et al. Inhibiting mitochondrial Na+\/Ca2+ exchange prevents sudden death in a guinea pig model of heart failure. Circ. Res. 115, 44\u201354 (2014).","journal-title":"Circ. Res."},{"key":"1167_CR134","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1161\/CIRCRESAHA.120.318562","volume":"128","author":"T Liu","year":"2021","unstructured":"Liu, T., Yang, N., Sidor, A. & O\u2019Rourke, B. MCU overexpression rescues inotropy and reverses heart failure by reducing SR Ca2+ leak. Circ. Res. 128, 1191\u20131204 (2021).","journal-title":"Circ. Res."},{"key":"1167_CR135","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/j.jacc.2022.09.041","volume":"80","author":"L Fossier","year":"2022","unstructured":"Fossier, L. et al. Enhanced mitochondrial calcium uptake suppresses atrial fibrillation associated with metabolic syndrome. J. Am. Coll. Cardiol. 80, 2205\u20132219 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR136","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1161\/CIRCRESAHA.118.312708","volume":"123","author":"S Dey","year":"2018","unstructured":"Dey, S., DeMazumder, D., Sidor, A., Foster, D. B. & O\u2019Rourke, B. Mitochondrial ROS drive sudden cardiac death and chronic proteome remodeling in heart failure. Circ. Res. 123, 356\u2013371 (2018).","journal-title":"Circ. Res."},{"key":"1167_CR137","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00395-021-00900-9","volume":"116","author":"B Hegyi","year":"2021","unstructured":"Hegyi, B. et al. Cardiomyocyte Na+ and Ca2+ mishandling drives vicious cycle involving CaMKII, ROS, and ryanodine receptors. Basic Res. Cardiol. 116, 58 (2021).","journal-title":"Basic Res. Cardiol."},{"key":"1167_CR138","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00395-024-01060-2","volume":"119","author":"E Bertero","year":"2024","unstructured":"Bertero, E., Popoiu, T. A. & Maack, C. Mitochondrial calcium in cardiac ischemia\/reperfusion injury and cardioprotection. Basic Res. Cardiol. 119, 569\u2013585 (2024).","journal-title":"Basic Res. Cardiol."},{"key":"1167_CR139","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202313520","volume":"157","author":"E Murphy","year":"2025","unstructured":"Murphy, E. & Eisner, D. A. How does mitochondrial Ca2+ change during ischemia and reperfusion? Implications for activation of the permeability transition pore. J. Gen. Physiol. 157, e202313520 (2025).","journal-title":"J. Gen. Physiol."},{"key":"1167_CR140","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/434578a","volume":"434","author":"A Halestrap","year":"2005","unstructured":"Halestrap, A. Biochemistry: a pore way to die. Nature 434, 578\u2013579 (2005).","journal-title":"Nature"},{"key":"1167_CR141","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1172\/JCI120849","volume":"128","author":"B Zhou","year":"2018","unstructured":"Zhou, B. & Tian, R. Mitochondrial dysfunction in pathophysiology of heart failure. J. Clin. Invest. 128, 3716\u20133726 (2018).","journal-title":"J. Clin. Invest."},{"key":"1167_CR142","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1172\/JCI31060","volume":"117","author":"H Nakayama","year":"2007","unstructured":"Nakayama, H. et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J. Clin. Invest. 117, 2431\u20132444 (2007).","journal-title":"J. Clin. Invest."},{"key":"1167_CR143","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.yjmcc.2017.09.009","volume":"113","author":"S Sommakia","year":"2017","unstructured":"Sommakia, S. et al. Mitochondrial cardiomyopathies feature increased uptake and diminished efflux of mitochondrial calcium. J. Mol. Cell. Cardiol. 113, 22\u201332 (2017).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR144","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.1073\/pnas.1513047112","volume":"112","author":"G Santulli","year":"2015","unstructured":"Santulli, G., Xie, W., Reiken, S. R. & Marks, A. R. Mitochondrial calcium overload is a key determinant in heart failure. Proc. Natl Acad. Sci. USA 112, 11389\u201311394 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR145","first-page":"H1053","volume":"272","author":"KH Desai","year":"1997","unstructured":"Desai, K. H. et al. Cardiovascular indexes in the mouse at rest and with exercise: new tools to study models of cardiac disease. Am. J. Physiol. 272, H1053\u2013H1061 (1997).","journal-title":"Am. J. Physiol."},{"key":"1167_CR146","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1469-7793.2001.00535.x","volume":"534","author":"D Georgakopoulos","year":"2001","unstructured":"Georgakopoulos, D. & Kass, D. Minimal force\u2013frequency modulation of inotropy and relaxation of in situ murine heart. J. Physiol. 534, 535\u2013545 (2001).","journal-title":"J. Physiol."},{"key":"1167_CR147","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1172\/JCI104136","volume":"39","author":"CB Chapman","year":"1960","unstructured":"Chapman, C. B., Fisher, J. N. & Sproule, B. J. Behavior of stroke volume at rest and during exercise in human beings. J. Clin. Invest. 39, 1208\u20131213 (1960).","journal-title":"J. Clin. Invest."},{"key":"1167_CR148","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1152\/jappl.1966.21.4.1150","volume":"21","author":"G Grimby","year":"1966","unstructured":"Grimby, G., Nilsson, N. J. & Saltin, B. Cardiac output during submaximal and maximal exercise in active middle-aged athletes. J. Appl. Physiol. 21, 1150\u20131156 (1966).","journal-title":"J. Appl. Physiol."},{"key":"1167_CR149","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/ncb2868","volume":"15","author":"X Pan","year":"2013","unstructured":"Pan, X. et al. The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat. Cell Biol. 15, 1464\u20131472 (2013).","journal-title":"Nat. Cell Biol."},{"key":"1167_CR150","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0021-9258(18)54024-2","volume":"268","author":"DA Cox","year":"1993","unstructured":"Cox, D. A. & Matlib, M. A. A role for the mitochondrial Na+\u2013Ca2+ exchanger in the regulation of oxidative phosphorylation in isolated heart mitochondria. J. Biol. Chem. 268, 938\u2013947 (1993).","journal-title":"J. Biol. Chem."},{"key":"1167_CR151","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1172\/JCI43171","volume":"120","author":"JW Elrod","year":"2010","unstructured":"Elrod, J. W. et al. Cyclophilin D controls mitochondrial pore-dependent Ca2+ exchange, metabolic flexibility, and propensity for heart failure in mice. J. Clin. Invest. 120, 3680\u20133687 (2010).","journal-title":"J. Clin. Invest."},{"key":"1167_CR152","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.yjmcc.2020.11.014","volume":"151","author":"B O\u2019Rourke","year":"2021","unstructured":"O\u2019Rourke, B., Ashok, D. & Liu, T. Mitochondrial Ca2+ in heart failure: not enough or too much? J. Mol. Cell. Cardiol. 151, 126\u2013134 (2021).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR153","doi-asserted-by":"publisher","first-page":"R1034","DOI":"10.1152\/ajpregu.00596.2011","volume":"302","author":"D Phillips","year":"2012","unstructured":"Phillips, D. et al. Regulation of oxidative phosphorylation complex activity: effects of tissue-specific metabolic stress within an allometric series and acute changes in workload. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R1034\u2013R1048 (2012).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"1167_CR154","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.cmet.2015.07.008","volume":"22","author":"AG Nickel","year":"2015","unstructured":"Nickel, A. G. et al. Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure. Cell Metab. 22, 472\u2013484 (2015).","journal-title":"Cell Metab."},{"key":"1167_CR155","doi-asserted-by":"publisher","first-page":"H397","DOI":"10.1152\/ajpheart.00088.2013","volume":"305","author":"L Garcia-Menendez","year":"2013","unstructured":"Garcia-Menendez, L., Karamanlidis, G., Kolwicz, S. & Tian, R. Substrain specific response to cardiac pressure overload in C57BL\/6 mice. Am. J. Physiol. Heart Circ. Physiol. 305, H397\u2013H402 (2013).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1167_CR156","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jacbts.2022.02.018","volume":"7","author":"M M\u00fcller","year":"2022","unstructured":"M\u00fcller, M. et al. Right heart failure in mice upon pressure overload is promoted by mitochondrial oxidative stress. JACC Basic Transl. Sci. 7, 658\u2013677 (2022).","journal-title":"JACC Basic Transl. Sci."},{"key":"1167_CR157","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1113\/JP279607","volume":"598","author":"JC Reil","year":"2020","unstructured":"Reil, J. C. et al. CaMKII activity contributes to homeometric autoregulation of the heart: a novel mechanism for the Anrep effect. J. Physiol. 598, 3129\u20133153 (2020).","journal-title":"J. Physiol."},{"key":"1167_CR158","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1161\/01.RES.0000145361.50017.aa","volume":"95","author":"W Wang","year":"2004","unstructured":"Wang, W. et al. Sustained \u03b21-adrenergic stimulation modulates cardiac contractility by Ca2+\/calmodulin kinase signaling pathway. Circ. Res. 95, 798\u2013806 (2004).","journal-title":"Circ. Res."},{"key":"1167_CR159","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev-pharmtox-051421-111814","volume":"63","author":"OE Reyes Gaido","year":"2023","unstructured":"Reyes Gaido, O. E. et al. CaMKII as a therapeutic target in cardiovascular disease. Annu. Rev. Pharmacol. Toxicol. 63, 249\u2013272 (2023).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1167_CR160","first-page":"qyad020","volume":"1","author":"C Morbach","year":"2023","unstructured":"Morbach, C. et al. Heart rate-corrected systolic ejection time: population-based reference values and differential prognostic utility in acute heart failure. Eur. Heart J. 1, qyad020 (2023).","journal-title":"Eur. Heart J."},{"key":"1167_CR161","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.7326\/0003-4819-12-8-1233","volume":"12","author":"G Herrmann","year":"1939","unstructured":"Herrmann, G. & Decherd, G. The chemical nature of heart failure. Ann. Intern. Med. 12, 1233\u20131244 (1939).","journal-title":"Ann. Intern. Med."},{"key":"1167_CR162","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12968-018-0491-6","volume":"20","author":"RE Gabr","year":"2018","unstructured":"Gabr, R. E. et al. Cardiac work is related to creatine kinase energy supply in human heart failure: a cardiovascular magnetic resonance spectroscopy study. J. Cardiovasc. Magn. Reson. 20, 81 (2018).","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"1167_CR163","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1073\/pnas.0408962102","volume":"102","author":"RG Weiss","year":"2005","unstructured":"Weiss, R. G., Gerstenblith, G. & Bottomley, P. A. ATP flux through creatine kinase in the normal, stressed, and failing human heart. Proc. Natl Acad. Sci. USA 102, 808\u2013813 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR164","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/01.CIR.103.11.1570","volume":"103","author":"Y Ye","year":"2001","unstructured":"Ye, Y., Gong, G., Ochiai, K., Liu, J. & Zhang, J. High-energy phosphate metabolism and creatine kinase in failing hearts: a new porcine model. Circulation 103, 1570\u20131576 (2001).","journal-title":"Circulation"},{"key":"1167_CR165","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.yjmcc.2005.05.003","volume":"39","author":"W Shen","year":"2005","unstructured":"Shen, W. et al. The fall in creatine levels and creatine kinase isozyme changes in the failing heart are reversible: complex post-transcriptional regulation of the components of the CK system. J. Mol. Cell. Cardiol. 39, 537\u2013544 (2005).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR166","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.yjmcc.2009.10.029","volume":"48","author":"W Shen","year":"2010","unstructured":"Shen, W., Vatner, D. E., Vatner, S. F. & Ingwall, J. S. Progressive loss of creatine maintains a near normal \u0394G ~ATP in transgenic mouse hearts with cardiomyopathy caused by overexpressing Gs\u03b1. J. Mol. Cell. Cardiol. 48, 591\u2013599 (2010).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR167","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1113\/JP270354","volume":"593","author":"V Sequeira","year":"2015","unstructured":"Sequeira, V. et al. Synergistic role of ADP and Ca2+ in diastolic myocardial stiffness. J. Physiol. 593, 3899\u20133916 (2015).","journal-title":"J. Physiol."},{"key":"1167_CR168","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1161\/01.CIR.96.4.1313","volume":"96","author":"R Tian","year":"1997","unstructured":"Tian, R., Nascimben, L., Ingwall, J. S. & Lorell, B. H. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 96, 1313\u20131319 (1997).","journal-title":"Circulation"},{"key":"1167_CR169","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1161\/01.RES.84.10.1137","volume":"84","author":"PP Dzeja","year":"1999","unstructured":"Dzeja, P. P., Vitkevicius, K. T., Redfield, M. M., Burnett, J. C. & Terzic, A. Adenylate kinase-catalyzed phosphotransfer in the myocardium : increased contribution in heart failure. Circ. Res. 84, 1137\u20131143 (1999).","journal-title":"Circ. Res."},{"key":"1167_CR170","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/eurjhf\/hfq174","volume":"12","author":"D Aksentijevic","year":"2010","unstructured":"Aksentijevic, D. et al. High-energy phosphotransfer in the failing mouse heart: role of adenylate kinase and glycolytic enzymes. Eur. J. Heart Fail. 12, 1282\u20131289 (2010).","journal-title":"Eur. J. Heart Fail."},{"key":"1167_CR171","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.yjmcc.2004.11.016","volume":"38","author":"M Ten Hove","year":"2005","unstructured":"Ten Hove, M. et al. Mechanisms of creatine depletion in chronically failing rat heart. J. Mol. Cell. Cardiol. 38, 309\u2013313 (2005).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR172","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1161\/01.CIR.100.18.1847","volume":"100","author":"S Neubauer","year":"1999","unstructured":"Neubauer, S. et al. Downregulation of the Na+\u2013creatine cotransporter in failing human myocardium and in experimental heart failure. Circulation 100, 1847\u20131850 (1999).","journal-title":"Circulation"},{"key":"1167_CR173","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/(SICI)1522-2683(19990701)20:10<2086::AID-ELPS2086>3.0.CO;2-4","volume":"20","author":"MY Heinke","year":"1999","unstructured":"Heinke, M. Y. et al. Changes in myocardial protein expression in pacing-induced canine heart failure. Electrophoresis 20, 2086\u20132093 (1999).","journal-title":"Electrophoresis"},{"key":"1167_CR174","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.cardfail.2009.04.010","volume":"15","author":"J Mar\u00edn-Garc\u00eda","year":"2009","unstructured":"Mar\u00edn-Garc\u00eda, J., Goldenthal, M. J., Damle, S., Pi, Y. & Moe, G. W. Regional distribution of mitochondrial dysfunction and apoptotic remodeling in pacing-induced heart failure. J. Card. Fail. 15, 700\u2013708 (2009).","journal-title":"J. Card. Fail."},{"key":"1167_CR175","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.144301","volume":"6","author":"MA Walker","year":"2021","unstructured":"Walker, M. A. et al. Acetylation of muscle creatine kinase negatively impacts high-energy phosphotransfer in heart failure. JCI Insight 6, e144301 (2021).","journal-title":"JCI Insight"},{"key":"1167_CR176","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0735-1097(02)01860-0","volume":"39","author":"SJ Park","year":"2002","unstructured":"Park, S. J. et al. Myocardial creatine kinase expression after left ventricular assist device support. J. Am. Coll. Cardiol. 39, 1773\u20131779 (2002).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR177","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1161\/CIRCRESAHA.112.300725","volume":"112","author":"CA Lygate","year":"2013","unstructured":"Lygate, C. A. et al. Living without creatine: unchanged exercise capacity and response to chronic myocardial infarction in creatine-deficient mice. Circ. Res. 112, 945\u2013955 (2013).","journal-title":"Circ. Res."},{"key":"1167_CR178","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo, E. et al. 2023 ESC Guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur. Heart J. 44, 3503\u20133626 (2023).","journal-title":"Eur. Heart J."},{"key":"1167_CR179","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMra0902923","volume":"364","author":"H Watkins","year":"2011","unstructured":"Watkins, H., Ashrafian, H. & Redwood, C. Inherited cardiomyopathies. N. Engl. J. Med. 364, 1643\u20131656 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR180","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"Authors\/Task Force Members","year":"2014","unstructured":"Authors\/Task Force Members 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 35, 2733\u20132779 (2014).","journal-title":"Eur. Heart J."},{"key":"1167_CR181","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 65, 1249\u20131254 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR182","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nrcardio.2011.159","volume":"9","author":"N Frey","year":"2012","unstructured":"Frey, N., Luedde, M. & Katus, H. A. Mechanisms of disease: hypertrophic cardiomyopathy. Nat. Rev. Cardiol. 9, 91\u2013100 (2012).","journal-title":"Nat. Rev. Cardiol."},{"key":"1167_CR183","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","volume":"83","author":"SR Ommen","year":"2024","unstructured":"Ommen, S. R. et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 83, 2324\u20132405 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR184","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jacc.2023.10.032","volume":"83","author":"G Finocchiaro","year":"2024","unstructured":"Finocchiaro, G., Westaby, J., Sheppard, M. N., Papadakis, M. & Sharma, S. Sudden cardiac death in young athletes: JACC state-of-the-art review. J. Am. Coll. Cardiol. 83, 350\u2013370 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR185","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/0092-8674(90)90274-I","volume":"62","author":"AA Geisterfer-Lowrance","year":"1990","unstructured":"Geisterfer-Lowrance, A. A. et al. A molecular basis for familial hypertrophic cardiomyopathy: a \u03b2 cardiac myosin heavy chain gene missense mutation. Cell 62, 999\u20131006 (1990).","journal-title":"Cell"},{"key":"1167_CR186","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/ng1295-438","volume":"11","author":"G Bonne","year":"1995","unstructured":"Bonne, G. et al. Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy. Nat. Genet. 11, 438\u2013440 (1995).","journal-title":"Nat. Genet."},{"key":"1167_CR187","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM199504203321603","volume":"332","author":"H Watkins","year":"1995","unstructured":"Watkins, H. et al. Mutations in the genes for cardiac troponin T and \u03b1-tropomyosin in hypertrophic cardiomyopathy. N. Engl. J. Med. 332, 1058\u20131064 (1995).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR188","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1161\/01.CIR.0000019070.70491.6D","volume":"105","author":"CY Ho","year":"2002","unstructured":"Ho, C. Y. et al. Assessment of diastolic function with doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105, 2992\u20132997 (2002).","journal-title":"Circulation"},{"key":"1167_CR189","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1113\/jphysiol.2008.155952","volume":"586","author":"A Belus","year":"2008","unstructured":"Belus, A. et al. The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils. J. Physiol. 586, 3639\u20133644 (2008).","journal-title":"J. Physiol."},{"key":"1167_CR190","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/cvr\/cvu127","volume":"103","author":"ER Witjas-Paalberends","year":"2014","unstructured":"Witjas-Paalberends, E. R. et al. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc. Res. 103, 248\u2013257 (2014).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR191","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/jmri.1880020616","volume":"2","author":"A De Roos","year":"1992","unstructured":"De Roos, A. et al. Cardiac metabolism in patients with dilated and hypertrophic cardio-myopathy: assessment with proton-decoupled P-31 MR spectroscopy. J. Magn. Reson. Imaging 2, 711\u2013719 (1992).","journal-title":"J. Magn. Reson. Imaging"},{"key":"1167_CR192","doi-asserted-by":"publisher","first-page":"34A","DOI":"10.1016\/S0002-9149(97)00456-6","volume":"80","author":"L Sieverding","year":"1997","unstructured":"Sieverding, L. et al. Proton-decoupled myocardial 31P NMR spectroscopy reveals decreased PCr\/Pi in patients with severe hypertrophic cardiomyopathy. Am. J. Cardiol. 80, 34A\u201340A (1997).","journal-title":"Am. J. Cardiol."},{"key":"1167_CR193","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1161\/01.CIR.97.25.2536","volume":"97","author":"W-I Jung","year":"1998","unstructured":"Jung, W.-I. et al. P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 97, 2536\u20132542 (1998).","journal-title":"Circulation"},{"key":"1167_CR194","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/S0735-1097(02)03009-7","volume":"41","author":"JG Crilley","year":"2003","unstructured":"Crilley, J. G. et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J. Am. Coll. Cardiol. 41, 1776\u20131782 (2003).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR195","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1161\/01.CIR.101.12.e121","volume":"101","author":"W-I Jung","year":"2000","unstructured":"Jung, W.-I. et al. Differences in cardiac energetics between patients with familial and nonfamilial hypertrophic cardiomyopathy. Circulation 101, e121\u2013e121 (2000).","journal-title":"Circulation"},{"key":"1167_CR196","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/eurheartj\/ehv120","volume":"36","author":"S Dass","year":"2015","unstructured":"Dass, S. et al. Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction. Eur. Heart J. 36, 1547\u20131554 (2015).","journal-title":"Eur. Heart J."},{"key":"1167_CR197","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1172\/JCI1940","volume":"101","author":"M Spindler","year":"1998","unstructured":"Spindler, M. et al. Diastolic dysfunction and altered energetics in the \u03b1MHC403\/+ mouse model of familial hypertrophic cardiomyopathy. J. Clin. Invest. 101, 1775\u20131783 (1998).","journal-title":"J. Clin. Invest."},{"key":"1167_CR198","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1161\/CIRCULATIONAHA.121.053575","volume":"144","author":"S Ranjbarvaziri","year":"2021","unstructured":"Ranjbarvaziri, S. et al. Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. Circulation 144, 1714\u20131731 (2021).","journal-title":"Circulation"},{"key":"1167_CR199","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009521","volume":"15","author":"MJ Previs","year":"2022","unstructured":"Previs, M. J. et al. Defects in the proteome and metabolome in human hypertrophic cardiomyopathy. Circ. Heart Fail. 15, e009521 (2022).","journal-title":"Circ. Heart Fail."},{"key":"1167_CR200","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s44161-022-00057-1","volume":"1","author":"W Wang","year":"2022","unstructured":"Wang, W. et al. Metabolic characterization of hypertrophic cardiomyopathy in human heart. Nat. Cardiovasc. Res. 1, 445\u2013461 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1167_CR201","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.3390\/ijms24054724","volume":"24","author":"J Moore","year":"2023","unstructured":"Moore, J. et al. Multi-omics profiling of hypertrophic cardiomyopathy reveals altered mechanisms in mitochondrial dynamics and excitation-contraction coupling. Int. J. Mol. Sci. 24, 4724 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1167_CR202","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/eurheartj\/ehad028","volume":"44","author":"EE Nollet","year":"2023","unstructured":"Nollet, E. E. et al. Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration. Eur. Heart J. 44, 1170\u20131185 (2023).","journal-title":"Eur. Heart J."},{"key":"1167_CR203","doi-asserted-by":"publisher","unstructured":"Kohlhaas, M. et al. Mitochondrial reactive oxygen species cause arrhythmias in hypertrophic cardiomyopathy. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2024.10.02.616214 (2024).","DOI":"10.1101\/2024.10.02.616214"},{"key":"1167_CR204","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/CIRCRESAHA.113.301055","volume":"112","author":"S Huke","year":"2013","unstructured":"Huke, S. et al. Focal energy deprivation underlies arrhythmia susceptibility in mice with calcium-sensitized myofilaments. Circ. Res. 112, 1334\u20131344 (2013).","journal-title":"Circ. Res."},{"key":"1167_CR205","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrcardio.2016.203","volume":"14","author":"DA Brown","year":"2017","unstructured":"Brown, D. A. et al. Mitochondrial function as a therapeutic target in heart failure. Nat. Rev. Cardiol. 14, 238\u2013250 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"1167_CR206","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1111\/bph.12461","volume":"171","author":"HH Szeto","year":"2014","unstructured":"Szeto, H. H. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br. J. Pharmacol. 171, 2029\u20132050 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"1167_CR207","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","volume":"127","author":"R Coppini","year":"2013","unstructured":"Coppini, R. et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 127, 575\u2013584 (2013).","journal-title":"Circulation"},{"key":"1167_CR208","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1161\/CIRCULATIONAHA.115.020086","volume":"134","author":"AS Helms","year":"2016","unstructured":"Helms, A. S. et al. Genotype-dependent and -independent calcium signaling dysregulation in human hypertrophic cardiomyopathy. Circulation 134, 1738\u20131748 (2016).","journal-title":"Circulation"},{"key":"1167_CR209","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1161\/CIRCULATIONAHA.118.034549","volume":"139","author":"SJ Lehman","year":"2019","unstructured":"Lehman, S. J. et al. Chronic calmodulin-kinase II activation drives disease progression in mutation-specific hypertrophic cardiomyopathy. Circulation 139, 1517\u20131529 (2019).","journal-title":"Circulation"},{"key":"1167_CR210","doi-asserted-by":"publisher","first-page":"10487","DOI":"10.1074\/jbc.RA118.002081","volume":"293","author":"P Robinson","year":"2018","unstructured":"Robinson, P. et al. Hypertrophic cardiomyopathy mutations increase myofilament Ca2+ buffering, alter intracellular Ca2+ handling, and stimulate Ca2+-dependent signaling. J. Biol. Chem. 293, 10487\u201310499 (2018).","journal-title":"J. Biol. Chem."},{"key":"1167_CR211","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.bbrc.2018.01.181","volume":"496","author":"S Okuda","year":"2018","unstructured":"Okuda, S. et al. CaMKII-mediated phosphorylation of RyR2 plays a crucial role in aberrant Ca2+ release as an arrhythmogenic substrate in cardiac troponin T-related familial hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 496, 1250\u20131256 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1167_CR212","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1172\/JCI26620","volume":"116","author":"S Wagner","year":"2006","unstructured":"Wagner, S. et al. Ca2+\/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J. Clin. Invest. 116, 3127\u20133138 (2006).","journal-title":"J. Clin. Invest."},{"key":"1167_CR213","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1172\/JCI27438","volume":"116","author":"J Backs","year":"2006","unstructured":"Backs, J., Song, K., Bezprozvannaya, S., Chang, S. & Olson, E. N. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J. Clin. Invest. 116, 1853\u20131864 (2006).","journal-title":"J. Clin. Invest."},{"key":"1167_CR214","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/01.CIR.0000157148.59308.F5","volume":"111","author":"GM Kuster","year":"2005","unstructured":"Kuster, G. M. et al. \u03b1-Adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation 111, 1192\u20131198 (2005).","journal-title":"Circulation"},{"key":"1167_CR215","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3324\/haematol.2014.114595","volume":"99","author":"CM Niemeyer","year":"2014","unstructured":"Niemeyer, C. M. RAS diseases in children. Haematologica 99, 1653\u20131662 (2014).","journal-title":"Haematologica"},{"key":"1167_CR216","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1172\/JCI44929","volume":"121","author":"X Wu","year":"2011","unstructured":"Wu, X. et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation. J. Clin. Invest. 121, 1009\u20131025 (2011).","journal-title":"J. Clin. Invest."},{"key":"1167_CR217","first-page":"H1720","volume":"309","author":"T Wilder","year":"2015","unstructured":"Wilder, T., Ryba, D. M., Wieczorek, D. F., Wolska, B. M. & Solaro, R. J. N-Acetylcysteine reverses diastolic dysfunction and hypertrophy in familial hypertrophic cardiomyopathy. Am. J. Physiol. 309, H1720\u2013H1730 (2015).","journal-title":"Am. J. Physiol."},{"key":"1167_CR218","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1161\/CIRCULATIONAHA.108.790501","volume":"119","author":"R Lombardi","year":"2009","unstructured":"Lombardi, R. et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 119, 1398\u20131407 (2009).","journal-title":"Circulation"},{"key":"1167_CR219","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jacc.2005.10.041","volume":"47","author":"AJ Marian","year":"2006","unstructured":"Marian, A. J., Senthil, V., Chen, S. N. & Lombardi, R. Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J. Am. Coll. Cardiol. 47, 827\u2013834 (2006).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR220","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCRESAHA.110.231514","volume":"108","author":"I Kehat","year":"2011","unstructured":"Kehat, I. et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ. Res. 108, 176\u2013183 (2011).","journal-title":"Circ. Res."},{"key":"1167_CR221","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.cell.2016.04.002","volume":"165","author":"J Davis","year":"2016","unstructured":"Davis, J. et al. A tension-based model distinguishes hypertrophic versus dilated cardiomyopathy. Cell 165, 1147\u20131159 (2016).","journal-title":"Cell"},{"key":"1167_CR222","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jacc.2010.12.044","volume":"58","author":"DF Dai","year":"2011","unstructured":"Dai, D. F. et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J. Am. Coll. Cardiol. 58, 73\u201382 (2011).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR223","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCRESAHA.110.232306","volume":"108","author":"DF Dai","year":"2011","unstructured":"Dai, D. F. et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and G\u03b1q overexpression-induced heart failure. Circ. Res. 108, 837\u2013846 (2011).","journal-title":"Circ. Res."},{"key":"1167_CR224","first-page":"47","volume":"116","author":"A Batzner","year":"2019","unstructured":"Batzner, A., Sch\u00e4fers, H.-J., Borisov, K. V. & Seggewi\u00df, H. Hypertrophic obstructive cardiomyopathy. Dtsch. Arztebl Int. 116, 47\u201353 (2019).","journal-title":"Dtsch. Arztebl Int."},{"key":"1167_CR225","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1056\/NEJMoa021332","volume":"348","author":"MS Maron","year":"2003","unstructured":"Maron, M. S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 348, 295\u2013303 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR226","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0140-6736(95)91267-3","volume":"346","author":"U Sigwart","year":"1995","unstructured":"Sigwart, U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346, 211\u2013214 (1995).","journal-title":"Lancet"},{"key":"1167_CR227","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green, E. M. et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351, 617\u2013621 (2016).","journal-title":"Science"},{"key":"1167_CR228","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","volume":"78","author":"SM Hegde","year":"2021","unstructured":"Hegde, S. M. et al. Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 78, 2518\u20132532 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR229","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","volume":"143","author":"S Saberi","year":"2021","unstructured":"Saberi, S. et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy. Circulation 143, 606\u2013608 (2021).","journal-title":"Circulation"},{"key":"1167_CR230","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamacardio.2024.2781","volume":"9","author":"MMY Lee","year":"2024","unstructured":"Lee, M. M. Y. et al. Aficamten and cardiopulmonary exercise test performance: a substudy of the SEQUOIA-HCM randomized clinical trial. JAMA Cardiol. 9, 990\u20131000 (2024).","journal-title":"JAMA Cardiol."},{"key":"1167_CR231","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","volume":"84","author":"A Masri","year":"2024","unstructured":"Masri, A. et al. Effect of aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy. J. Am. Coll. Cardiol. 84, 1806\u20131817 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR232","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/jimd.12427","volume":"45","author":"J Dudek","year":"2022","unstructured":"Dudek, J. & Maack, C. Mechano-energetic aspects of Barth syndrome. J. Inherit. Metab. Dis. 45, 82\u201398 (2022).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1167_CR233","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0022-510X(83)90209-5","volume":"62","author":"PG Barth","year":"1983","unstructured":"Barth, P. G. et al. An X-linked mitochondrial disease affecting cardiac muscle, skeletal muscle and neutrophil leucocytes. J. Neurol. Sci. 62, 327\u2013355 (1983).","journal-title":"J. Neurol. Sci."},{"key":"1167_CR234","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00246-022-02846-8","volume":"43","author":"S Chowdhury","year":"2022","unstructured":"Chowdhury, S. et al. Longitudinal observational study of cardiac outcome risk factor prediction in children, adolescents, and adults with barth syndrome. Pediatr. Cardiol. 43, 1251\u20131263 (2022).","journal-title":"Pediatr. Cardiol."},{"key":"1167_CR235","first-page":"H2122","volume":"301","author":"CT Spencer","year":"2011","unstructured":"Spencer, C. T. et al. Impaired cardiac reserve and severely diminished skeletal muscle O2 utilization mediate exercise intolerance in Barth syndrome. Am. J. Physiol. 301, H2122\u2013H2129 (2011).","journal-title":"Am. J. Physiol."},{"key":"1167_CR236","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s00246-005-0873-z","volume":"26","author":"CT Spencer","year":"2005","unstructured":"Spencer, C. T. et al. Ventricular arrhythmia in the X-linked cardiomyopathy Barth syndrome. Pediatr. Cardiol. 26, 632\u2013637 (2005).","journal-title":"Pediatr. Cardiol."},{"key":"1167_CR237","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nm.3545","volume":"20","author":"G Wang","year":"2014","unstructured":"Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20, 616\u2013623 (2014).","journal-title":"Nat. Med."},{"key":"1167_CR238","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.scr.2013.05.005","volume":"11","author":"J Dudek","year":"2013","unstructured":"Dudek, J. et al. Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome. Stem Cell Res. 11, 806\u2013819 (2013).","journal-title":"Stem Cell Res."},{"key":"1167_CR239","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1161\/CIRCRESAHA.119.315956","volume":"126","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. AAV gene therapy prevents and reverses heart failure in a murine knockout model of barth syndrome. Circ. Res. 126, 1024\u20131039 (2020).","journal-title":"Circ. Res."},{"key":"1167_CR240","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1161\/CIRCULATIONAHA.120.048698","volume":"143","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Increased reactive oxygen species-mediated Ca2+\/calmodulin-dependent protein kinase II activation contributes to calcium handling abnormalities and impaired contraction in Barth syndrome. Circulation 143, 1894\u20131911 (2021).","journal-title":"Circulation"},{"key":"1167_CR241","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1161\/CIRCULATIONAHA.121.053755","volume":"144","author":"E Bertero","year":"2021","unstructured":"Bertero, E. et al. Loss of mitochondrial Ca2+ uniporter limits inotropic reserve and provides trigger and substrate for arrhythmias in Barth syndrome cardiomyopathy. Circulation 144, 1694\u20131713 (2021).","journal-title":"Circulation"},{"key":"1167_CR242","doi-asserted-by":"publisher","first-page":"16383","DOI":"10.1073\/pnas.2000640117","volume":"117","author":"S Ghosh","year":"2020","unstructured":"Ghosh, S. et al. An essential role for cardiolipin in the stability and function of the mitochondrial calcium uniporter. Proc. Natl Acad. Sci. USA 117, 16383\u201316390 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR243","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/hmg\/ddab254","volume":"31","author":"S Ghosh","year":"2022","unstructured":"Ghosh, S. et al. MCU-complex-mediated mitochondrial calcium signaling is impaired in Barth syndrome. Hum. Mol. Genet. 31, 376\u2013385 (2022).","journal-title":"Hum. Mol. Genet."},{"key":"1167_CR244","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/1873-3468.13973","volume":"595","author":"RLS Goncalves","year":"2021","unstructured":"Goncalves, R. L. S., Schlame, M., Bartelt, A., Brand, M. D. & Hotam\u0131\u015fl\u0131gil, G. S. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide\/H2O2 production in heart and skeletal muscle mitochondria. FEBS Lett. 595, 415\u2013432 (2021).","journal-title":"FEBS Lett."},{"key":"1167_CR245","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00395-023-01017-x","volume":"118","author":"I Kutschka","year":"2023","unstructured":"Kutschka, I. et al. Activation of the integrated stress response rewires cardiac metabolism in Barth syndrome. Basic Res. Cardiol. 118, 47 (2023).","journal-title":"Basic Res. Cardiol."},{"key":"1167_CR246","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/jimd.12453","volume":"45","author":"R Thompson","year":"2022","unstructured":"Thompson, R. et al. Current and future treatment approaches for Barth syndrome. J. Inherit. Metab. Dis. 45, 17\u201328 (2022).","journal-title":"J. Inherit. Metab. Dis."},{"key":"1167_CR247","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/hum.2018.020","volume":"30","author":"S Suzuki-Hatano","year":"2019","unstructured":"Suzuki-Hatano, S. et al. AAV-mediated TAZ gene replacement restores mitochondrial and cardioskeletal function in Barth syndrome. Hum. Gene. Ther. 30, 139\u2013154 (2019).","journal-title":"Hum. Gene. Ther."},{"key":"1167_CR248","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64368-y","volume":"14","author":"S Russo","year":"2024","unstructured":"Russo, S., De Rasmo, D., Rossi, R., Signorile, A. & Lobasso, S. SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome. Sci. Rep. 14, 13655 (2024).","journal-title":"Sci. Rep."},{"key":"1167_CR249","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24231-4","volume":"12","author":"S Russo","year":"2022","unstructured":"Russo, S., De Rasmo, D., Signorile, A., Corcelli, A. & Lobasso, S. Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice. Sci. Rep. 12, 19847 (2022).","journal-title":"Sci. Rep."},{"key":"1167_CR250","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41436-020-01006-8","volume":"23","author":"W Reid Thompson","year":"2021","unstructured":"Reid Thompson, W. et al. A phase 2\/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. Genet. Med. 23, 471\u2013478 (2021).","journal-title":"Genet. Med."},{"key":"1167_CR251","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101138","volume":"26","author":"WR Thompson","year":"2024","unstructured":"Thompson, W. R. et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet. Med. 26, 101138 (2024).","journal-title":"Genet. Med."},{"key":"1167_CR252","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1056\/NEJMoa052256","volume":"355","author":"TE Owan","year":"2006","unstructured":"Owan, T. E. et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 355, 251\u2013259 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR253","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","volume":"22","author":"A Groenewegen","year":"2020","unstructured":"Groenewegen, A., Rutten, F. H., Mosterd, A. & Hoes, A. W. Epidemiology of heart failure. Eur. J. Heart Fail. 22, 1342\u20131356 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1167_CR254","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1056\/NEJMcp2305181","volume":"392","author":"A Cannata","year":"2025","unstructured":"Cannata, A. & McDonagh, T. A. Heart failure with preserved ejection fraction. N. Engl. J. Med. 392, 173\u2013184 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR255","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","volume":"40","author":"CSP Lam","year":"2019","unstructured":"Lam, C. S. P. et al. Sex differences in heart failure. Eur. Heart J. 40, 3859\u20133868c (2019).","journal-title":"Eur. Heart J."},{"key":"1167_CR256","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1056\/NEJMoa051530","volume":"355","author":"RS Bhatia","year":"2006","unstructured":"Bhatia, R. S. et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N. Engl. J. Med. 355, 260\u2013269 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR257","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ijcard.2018.04.001","volume":"271","author":"KW Streng","year":"2018","unstructured":"Streng, K. W. et al. Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. Int. J. Cardiol. 271, 132\u2013139 (2018).","journal-title":"Int. J. Cardiol."},{"key":"1167_CR258","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler, J. et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur. Heart J. 43, 416\u2013426 (2022).","journal-title":"Eur. Heart J."},{"key":"1167_CR259","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","volume":"63","author":"E Kraigher-Krainer","year":"2014","unstructured":"Kraigher-Krainer, E. et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 63, 447\u2013456 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR260","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1093\/eurheartj\/ehv510","volume":"37","author":"M Cikes","year":"2016","unstructured":"Cikes, M. & Solomon, S. D. Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. Eur. Heart J. 37, 1642\u20131650 (2016).","journal-title":"Eur. Heart J."},{"key":"1167_CR261","doi-asserted-by":"publisher","unstructured":"Borlaug, B. A. Evaluation and management of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. https:\/\/doi.org\/10.1038\/s41569-020-0363-2 (2020).","DOI":"10.1038\/s41569-020-0363-2"},{"key":"1167_CR262","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ejhf.1741","volume":"22","author":"B Pieske","year":"2020","unstructured":"Pieske, B. et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur. J. Heart Fail. 22, 391\u2013412 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1167_CR263","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1161\/CIRCRESAHA.111.245092","volume":"109","author":"MR Bristow","year":"2011","unstructured":"Bristow, M. R. Treatment of chronic heart failure with \u03b2-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ. Res. 109, 1176\u20131194 (2011).","journal-title":"Circ. Res."},{"key":"1167_CR264","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/CIRCULATIONAHA.122.059280","volume":"146","author":"S Rosch","year":"2022","unstructured":"Rosch, S. et al. Characteristics of heart failure with preserved ejection fraction across the range of left ventricular ejection fraction. Circulation 146, 506\u2013518 (2022).","journal-title":"Circulation"},{"key":"1167_CR265","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1113\/JP281845","volume":"599","author":"E Jones","year":"2021","unstructured":"Jones, E. et al. Phenotyping heart failure using model-based analysis and physiology-informed machine learning. J. Physiol. 599, 4991\u20135013 (2021).","journal-title":"J. Physiol."},{"key":"1167_CR266","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.011833","volume":"17","author":"J Almeida-Coelho","year":"2024","unstructured":"Almeida-Coelho, J. et al. Myosin-inhibitor mavacamten acutely enhances cardiomyocyte diastolic compliance in heart failure with preserved ejection fraction. Circ. Heart Fail. 17, e011833 (2024).","journal-title":"Circ. Heart Fail."},{"key":"1167_CR267","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1161\/CIRCULATIONAHA.120.052414","volume":"143","author":"MI Aslam","year":"2021","unstructured":"Aslam, M. I. et al. Reduced right ventricular sarcomere contractility in heart failure with preserved ejection fraction and severe obesity. Circulation 143, 965\u2013967 (2021).","journal-title":"Circulation"},{"key":"1167_CR268","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jamacardio.2024.3810","volume":"10","author":"SJ Shah","year":"2025","unstructured":"Shah, S. J. et al. Cardiac myosin inhibition in heart failure with normal and supranormal ejection fraction: primary results of the EMBARK-HFpEF trial. JAMA Cardiol. 10, 170\u2013175 (2025).","journal-title":"JAMA Cardiol."},{"key":"1167_CR269","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cvr\/cvae095","volume":"120","author":"M Trum","year":"2024","unstructured":"Trum, M. et al. Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF. Cardiovasc. Res. 120, 999\u20131010 (2024).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR270","doi-asserted-by":"publisher","unstructured":"Mira Hernandez, J. et al. Differential sex-dependent susceptibility to diastolic dysfunction and arrhythmia in cardiomyocytes from obese diabetic HFpEF model. Cardiovasc. Res. https:\/\/doi.org\/10.1093\/cvr\/cvae070 (2024).","DOI":"10.1093\/cvr\/cvae070"},{"key":"1167_CR271","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.123.324103","volume":"135","author":"A Yoshii","year":"2024","unstructured":"Yoshii, A. et al. Blunted cardiac mitophagy in response to metabolic stress contributes to HFpEF. Circ. Res. 135, 1004\u20131017 (2024).","journal-title":"Circ. Res."},{"key":"1167_CR272","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006240","volume":"12","author":"OF AbouEzzeddine","year":"2019","unstructured":"AbouEzzeddine, O. F. et al. Myocardial energetics in heart failure with preserved ejection fraction. Circ. Heart Fail. 12, e006240 (2019).","journal-title":"Circ. Heart Fail."},{"key":"1167_CR273","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","volume":"69","author":"A Pandey","year":"2017","unstructured":"Pandey, A. et al. Relationship between physical activity, body mass index, and risk of heart failure. J. Am. Coll. Cardiol. 69, 1129\u20131142 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR274","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","volume":"43","author":"C Adamson","year":"2022","unstructured":"Adamson, C. et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur. Heart J. 43, 4406\u20134417 (2022).","journal-title":"Eur. Heart J."},{"key":"1167_CR275","doi-asserted-by":"publisher","first-page":"14211","DOI":"10.1073\/pnas.2336140100","volume":"100","author":"M Ehrhart-Bornstein","year":"2003","unstructured":"Ehrhart-Bornstein, M. et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl Acad. Sci. USA 100, 14211\u201314216 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR276","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","volume":"132","author":"A-C Huby","year":"2015","unstructured":"Huby, A.-C. et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 132, 2134\u20132145 (2015).","journal-title":"Circulation"},{"key":"1167_CR277","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","volume":"137","author":"M Packer","year":"2018","unstructured":"Packer, M. Leptin-aldosterone-neprilysin axis. Circulation 137, 1614\u20131631 (2018).","journal-title":"Circulation"},{"key":"1167_CR278","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.echo.2006.03.033","volume":"19","author":"V Di Bello","year":"2006","unstructured":"Di Bello, V. et al. Obesity cardiomyopathy: is it a reality? An ultrasonic tissue characterization study. J. Am. Soc. Echocardiogr. 19, 1063\u20131071 (2006).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"1167_CR279","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V. & Borlaug, B. A. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 136, 6\u201319 (2017).","journal-title":"Circulation"},{"key":"1167_CR280","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ejhf.3092","volume":"26","author":"SE Litwin","year":"2024","unstructured":"Litwin, S. E. et al. Obesity in heart failure with preserved ejection fraction: insights from the REDUCE LAP-HF II trial. Eur. J. Heart Fail. 26, 177\u2013189 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"1167_CR281","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s44161-024-00516-x","volume":"3","author":"M Meddeb","year":"2024","unstructured":"Meddeb, M. et al. Myocardial ultrastructure of human heart failure with preserved ejection fraction. Nat. Cardiovasc. Res. 3, 907\u2013914 (2024).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1167_CR282","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/ejhf.1059","volume":"20","author":"AP Louren\u00e7o","year":"2018","unstructured":"Louren\u00e7o, A. P. et al. An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur. J. Heart Fail. 20, 216\u2013227 (2018).","journal-title":"Eur. J. Heart Fail."},{"key":"1167_CR283","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-019-1100-z","volume":"568","author":"GG Schiattarella","year":"2019","unstructured":"Schiattarella, G. G. et al. Nitrosative stress drives heart failure with preserved ejection fraction. Nature 568, 351\u2013356 (2019).","journal-title":"Nature"},{"key":"1167_CR284","doi-asserted-by":"publisher","unstructured":"Pepin, M.E. et al. Mitochondrial NNT promotes diastolic dysfunction in cardiometabolic HFpEF. Circ. Res. https:\/\/doi.org\/10.1161\/CIRCRESAHA.125.326154 (2025).","DOI":"10.1161\/CIRCRESAHA.125.326154"},{"key":"1167_CR285","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00395-020-00835-7","volume":"115","author":"M Dia","year":"2020","unstructured":"Dia, M. et al. Reduced reticulum-mitochondria Ca2+ transfer is an early and reversible trigger of mitochondrial dysfunctions in diabetic cardiomyopathy. Basic Res. Cardiol. 115, 74 (2020).","journal-title":"Basic Res. Cardiol."},{"key":"1167_CR286","doi-asserted-by":"crossref","first-page":"H615","DOI":"10.1152\/ajpcell.00206.2021","volume":"321","author":"S Hamilton","year":"2021","unstructured":"Hamilton, S. et al. MCU overexpression evokes disparate dose-dependent effects on mito-ROS and spontaneous Ca2+ release in hypertrophic rat cardiomyocytes. Am. J. Physiol. 321, H615\u2013H632 (2021).","journal-title":"Am. J. Physiol."},{"key":"1167_CR287","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12933-024-02329-5","volume":"23","author":"M Cherpaz","year":"2024","unstructured":"Cherpaz, M. et al. Myocardial transcriptomic analysis of diabetic patients with aortic stenosis: key role for mitochondrial calcium signaling. Cardiovasc. Diabetol. 23, 239 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"1167_CR288","doi-asserted-by":"publisher","DOI":"10.1111\/apha.13378","volume":"228","author":"D Miranda-Silva","year":"2020","unstructured":"Miranda-Silva, D. et al. Disturbed cardiac mitochondrial and cytosolic calcium handling in a metabolic risk-related rat model of heart failure with preserved ejection fraction. Acta Physiol. 228, e13378 (2020).","journal-title":"Acta Physiol."},{"key":"1167_CR289","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41569-024-00996-1","volume":"21","author":"JY Chyou","year":"2024","unstructured":"Chyou, J. Y., Qin, H., Butler, J., Voors, A. A. & Lam, C. S. P. Sex-related similarities and differences in responses to heart failure therapies. Nat. Rev. Cardiol. 21, 498\u2013516 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1167_CR290","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1161\/CIRCULATIONAHA.124.070872","volume":"151","author":"N Bergan","year":"2025","unstructured":"Bergan, N. et al. Systematic review, meta-analysis, and population study to determine the biologic sex ratio in dilated cardiomyopathy. Circulation 151, 442\u2013459 (2025).","journal-title":"Circulation"},{"key":"1167_CR291","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jchf.2019.01.004","volume":"7","author":"AL Beale","year":"2019","unstructured":"Beale, A. L. et al. Sex differences in heart failure with preserved ejection fraction pathophysiology: a detailed invasive hemodynamic and echocardiographic analysis. JACC Heart Fail. 7, 239\u2013249 (2019).","journal-title":"JACC Heart Fail."},{"key":"1167_CR292","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1093\/eurjpc\/zwae256","volume":"31","author":"W Qiu","year":"2024","unstructured":"Qiu, W. et al. Sex differences in long-term heart failure prognosis: a comprehensive meta-analysis. Eur. J. Prev. Cardiol. 31, 2013\u20132023 (2024).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"1167_CR293","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/0002-9149(93)90678-6","volume":"72","author":"HM Krumholz","year":"1993","unstructured":"Krumholz, H. M., Larson, M. & Levy, D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am. J. Cardiol. 72, 310\u2013313 (1993).","journal-title":"Am. J. Cardiol."},{"key":"1167_CR294","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S0735-1097(98)00347-7","volume":"32","author":"PS Douglas","year":"1998","unstructured":"Douglas, P. S. et al. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J. Am. Coll. Cardiol. 32, 1118\u20131125 (1998).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR295","first-page":"R1597","volume":"298","author":"D Fliegner","year":"2010","unstructured":"Fliegner, D. et al. Female sex and estrogen receptor-\u03b2 attenuate cardiac remodeling and apoptosis in pressure overload. Am. J. Physiol. 298, R1597\u2013R1606 (2010).","journal-title":"Am. J. Physiol."},{"key":"1167_CR296","first-page":"H469","volume":"288","author":"M Skavdahl","year":"2005","unstructured":"Skavdahl, M. et al. Estrogen receptor-\u03b2 mediates male-female differences in the development of pressure overload hypertrophy. Am. J. Physiol. 288, H469\u2013H476 (2005).","journal-title":"Am. J. Physiol."},{"key":"1167_CR297","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cardfail.2007.10.024","volume":"14","author":"RD Patten","year":"2008","unstructured":"Patten, R. D. et al. 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J. Card. Fail. 14, 245\u2013253 (2008).","journal-title":"J. Card. Fail."},{"key":"1167_CR298","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/hc3601.095577","volume":"104","author":"M van Eickels","year":"2001","unstructured":"van Eickels, M. et al. 17\u03b2-Estradiol attenuates the development of pressure-overload hypertrophy. Circulation 104, 1419\u20131423 (2001).","journal-title":"Circulation"},{"key":"1167_CR299","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1161\/01.ATV.0000223344.11128.23","volume":"26","author":"FA Babiker","year":"2006","unstructured":"Babiker, F. A. et al. Estrogen receptor \u03b2 protects the murine heart against left ventricular hypertrophy. Arterioscler. Thromb. Vasc. Biol. 26, 1524\u20131530 (2006).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1167_CR300","doi-asserted-by":"publisher","first-page":"7228","DOI":"10.1074\/jbc.273.13.7228","volume":"273","author":"A Clerk","year":"1998","unstructured":"Clerk, A., Fuller, S. J., Michael, A. & Sugden, P. H. Stimulation of \u2018stress-regulated\u2019 mitogen-activated protein kinases (stress-activated protein kinases\/c-Jun N-terminal kinases and p38-mitogen-activated protein kinases) in perfused rat hearts by oxidative and other stresses. J. Biol. Chem. 273, 7228\u20137234 (1998).","journal-title":"J. Biol. Chem."},{"key":"1167_CR301","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3389\/fendo.2019.00557","volume":"10","author":"R Ventura-Clapier","year":"2019","unstructured":"Ventura-Clapier, R., Piquereau, J., Veksler, V. & Garnier, A. Estrogens, estrogen receptors effects on cardiac and skeletal muscle mitochondria. Front. Endocrinol. 10, 557 (2019).","journal-title":"Front. Endocrinol."},{"key":"1167_CR302","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/ijms23031118","volume":"23","author":"S Beikoghli Kalkhoran","year":"2022","unstructured":"Beikoghli Kalkhoran, S. & Kararigas, G. Oestrogenic regulation of mitochondrial dynamics. Int. J. Mol. Sci. 23, 1118 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1167_CR303","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10863-017-9704-1","volume":"49","author":"CM Klinge","year":"2017","unstructured":"Klinge, C. M. Estrogens regulate life and death in mitochondria. J. Bioenerg. Biomembr. 49, 307\u2013324 (2017).","journal-title":"J. Bioenerg. Biomembr."},{"key":"1167_CR304","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mce.2008.04.013","volume":"290","author":"JW Simpkins","year":"2008","unstructured":"Simpkins, J. W., Yang, S.-H., Sarkar, S. N. & Pearce, V. Estrogen actions on mitochondria \u2014 physiological and pathological implications. Mol. Cell. Endocrinol. 290, 51\u201359 (2008).","journal-title":"Mol. Cell. Endocrinol."},{"key":"1167_CR305","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1073\/pnas.0306948101","volume":"101","author":"S-H Yang","year":"2004","unstructured":"Yang, S.-H. et al. Mitochondrial localization of estrogen receptor \u03b2. Proc. Natl Acad. Sci. USA 101, 4130\u20134135 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1167_CR306","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cardiores.2007.02.001","volume":"74","author":"B Colom","year":"2007","unstructured":"Colom, B., Oliver, J., Roca, P. & Garcia-Palmer, F. J. Caloric restriction and gender modulate cardiac muscle mitochondrial H2O2 production and oxidative damage. Cardiovasc. Res. 74, 456\u2013465 (2007).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR307","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13125","volume":"5","author":"AR Khalifa","year":"2017","unstructured":"Khalifa, A. R. et al. Sex-specific differences in mitochondria biogenesis, morphology, respiratory function, and ROS homeostasis in young mouse heart and brain. Physiol. Rep. 5, e13125 (2017).","journal-title":"Physiol. Rep."},{"key":"1167_CR308","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00395-023-00988-1","volume":"118","author":"RT Clements","year":"2023","unstructured":"Clements, R. T. et al. Sexual dimorphism in bidirectional SR\u2013mitochondria crosstalk in ventricular cardiomyocytes. Basic Res. Cardiol. 118, 15 (2023).","journal-title":"Basic Res. Cardiol."},{"key":"1167_CR309","doi-asserted-by":"publisher","first-page":"717881","DOI":"10.3389\/fcell.2022.717881","volume":"10","author":"S Kamada","year":"2022","unstructured":"Kamada, S., Takeiwa, T., Ikeda, K., Horie, K. & Inoue, S. Emerging roles of COX7RP and mitochondrial oxidative phosphorylation in breast cancer. Front. Cell Dev. Biol. 10, 717881 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1167_CR310","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.cmet.2022.09.005","volume":"34","author":"E Fern\u00e1ndez-Vizarra","year":"2022","unstructured":"Fern\u00e1ndez-Vizarra, E. et al. Two independent respiratory chains adapt OXPHOS performance to glycolytic switch. Cell Metab. 34, 1792\u20131808.e1796 (2022).","journal-title":"Cell Metab."},{"key":"1167_CR311","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.yjmcc.2004.04.023","volume":"37","author":"Y Arieli","year":"2004","unstructured":"Arieli, Y., Gursahani, H., Eaton, M. M., Hernandez, L. A. & Schaefer, S. Gender modulation of Ca2+ uptake in cardiac mitochondria. J. Mol. Cell. Cardiol. 37, 507\u2013513 (2004).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR312","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1113\/EP085248","volume":"100","author":"H Chweih","year":"2015","unstructured":"Chweih, H., Castilho, R. F. & Figueira, T. R. Tissue and sex specificities in Ca2+ handling by isolated mitochondria in conditions avoiding the permeability transition. Exp. Physiol. 100, 1073\u20131092 (2015).","journal-title":"Exp. Physiol."},{"key":"1167_CR313","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1161\/CIRCULATIONAHA.119.042267","volume":"140","author":"D Tong","year":"2019","unstructured":"Tong, D. et al. Female sex is protective in a preclinical model of heart failure with preserved ejection fraction. Circulation 140, 1769\u20131771 (2019).","journal-title":"Circulation"},{"key":"1167_CR314","doi-asserted-by":"publisher","first-page":"H522","DOI":"10.1152\/ajpheart.00733.2023","volume":"326","author":"AM Troy","year":"2024","unstructured":"Troy, A. M. et al. Impact of ovary-intact menopause in a mouse model of heart failure with preserved ejection fraction. Am. J. Physiol. Heart Circ. Physiol. 326, H522\u2013h537 (2024).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"1167_CR315","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/CIRCULATIONAHA.121.056589","volume":"144","author":"M Abdellatif","year":"2021","unstructured":"Abdellatif, M., Sedej, S. & Kroemer, G. NAD+ Metabolism in cardiac health, aging, and disease. Circulation 144, 1795\u20131817 (2021).","journal-title":"Circulation"},{"key":"1167_CR316","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1161\/CIRCULATIONAHA.116.022495","volume":"134","author":"CF Lee","year":"2016","unstructured":"Lee, C. F. et al. Normalization of NAD+ redox balance as a therapy for heart failure. Circulation 134, 883\u2013894 (2016).","journal-title":"Circulation"},{"key":"1167_CR317","doi-asserted-by":"publisher","first-page":"eabd7064","DOI":"10.1126\/scitranslmed.abd7064","volume":"13","author":"M Abdellatif","year":"2021","unstructured":"Abdellatif, M. et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci. Transl. Med. 13, eabd7064 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1167_CR318","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1161\/CIRCRESAHA.120.317046","volume":"128","author":"D Tong","year":"2021","unstructured":"Tong, D. et al. NAD+ repletion reverses heart failure with preserved ejection fraction. Circ. Res. 128, 1629\u20131641 (2021).","journal-title":"Circ. Res."},{"key":"1167_CR319","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jacbts.2024.01.011","volume":"9","author":"YC Koay","year":"2024","unstructured":"Koay, Y. C. et al. The efficacy of risk factor modification compared to NAD+ repletion in diastolic heart failure. JACC Basic Transl. Sci. 9, 733\u2013750 (2024).","journal-title":"JACC Basic Transl. Sci."},{"key":"1167_CR320","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.yjmcc.2021.12.015","volume":"165","author":"X Liu","year":"2022","unstructured":"Liu, X. et al. Mitochondrial protein hyperacetylation underpins heart failure with preserved ejection fraction in mice. J. Mol. Cell. Cardiol. 165, 76\u201385 (2022).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1167_CR321","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1161\/CIRCRESAHA.123.322381","volume":"134","author":"YC Wang","year":"2024","unstructured":"Wang, Y. C. et al. Indole-3-propionic acid protects against heart failure with preserved ejection fraction. Circ. Res. 134, 371\u2013389 (2024).","journal-title":"Circ. Res."},{"key":"1167_CR322","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1093\/cvr\/cvab328","volume":"118","author":"CM Loescher","year":"2022","unstructured":"Loescher, C. M., Hobbach, A. J. & Linke, W. A. Titin (TTN): from molecule to modifications, mechanics, and medical significance. Cardiovasc. Res. 118, 2903\u20132918 (2022).","journal-title":"Cardiovasc. Res."},{"key":"1167_CR323","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1161\/CIRCULATIONAHA.116.026099","volume":"137","author":"N Diguet","year":"2018","unstructured":"Diguet, N. et al. Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. Circulation 137, 2256\u20132273 (2018).","journal-title":"Circulation"},{"key":"1167_CR324","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.123.066039","volume":"148","author":"MA Walker","year":"2023","unstructured":"Walker, M. A. et al. Raising NAD+ level stimulates short-chain dehydrogenase\/reductase proteins to alleviate heart failure independent of mitochondrial protein deacetylation. Circulation 148, 2038\u20132057 (2023).","journal-title":"Circulation"},{"key":"1167_CR325","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1093\/hmg\/ddy278","volume":"27","author":"N Vignier","year":"2018","unstructured":"Vignier, N. et al. Rescue of biosynthesis of nicotinamide adenine dinucleotide protects the heart in cardiomyopathy caused by lamin A\/C gene mutation. Hum. Mol. Genet. 27, 3870\u20133880 (2018).","journal-title":"Hum. Mol. Genet."},{"key":"1167_CR326","doi-asserted-by":"publisher","unstructured":"Abdellatif, M. et al. Autophagy is required for the therapeutic effects of the NAD+ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction. Eur. Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf062 (2025).","DOI":"10.1093\/eurheartj\/ehaf062"},{"key":"1167_CR327","volume":"2","author":"JL Horton","year":"2016","unstructured":"Horton, J. L. et al. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight 2, e84897 (2016).","journal-title":"JCI Insight"},{"key":"1167_CR328","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jacbts.2022.06.012","volume":"7","author":"DD Wang","year":"2022","unstructured":"Wang, D. D. et al. Safety and tolerability of nicotinamide riboside in heart failure with reduced ejection fraction. JACC Basic Transl. Sci. 7, 1183\u20131196 (2022).","journal-title":"JACC Basic Transl. Sci."},{"key":"1167_CR329","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1172\/JCI138538","volume":"130","author":"B Zhou","year":"2020","unstructured":"Zhou, B. et al. Boosting NAD level suppresses inflammatory activation of PBMCs in heart failure. J. Clin. Invest. 130, 6054\u20136063 (2020).","journal-title":"J. Clin. Invest."},{"key":"1167_CR330","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.jacc.2019.02.051","volume":"73","author":"MA Psotka","year":"2019","unstructured":"Psotka, M. A. et al. Cardiac calcitropes, myotropes, and mitotropes: JACC review topic of the week. J. Am. Coll. Cardiol. 73, 2345\u20132353 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR331","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s44161-024-00576-z","volume":"3","author":"L Haghighat","year":"2024","unstructured":"Haghighat, L., DeJong, C. & Teerlink, J. R. New and future heart failure drugs. Nat. Cardiovasc. Res. 3, 1389\u20131407 (2024).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1167_CR332","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ehj.2004.02.018","volume":"25","author":"L Lee","year":"2004","unstructured":"Lee, L., Horowitz, J. & Frenneaux, M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur. Heart J. 25, 634\u2013641 (2004).","journal-title":"Eur. Heart J."},{"key":"1167_CR333","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1161\/CIRCULATIONAHA.105.551457","volume":"112","author":"L Lee","year":"2005","unstructured":"Lee, L. et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112, 3280\u20133288 (2005).","journal-title":"Circulation"},{"key":"1167_CR334","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","volume":"122","author":"K Abozguia","year":"2010","unstructured":"Abozguia, K. et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122, 1562\u20131569 (2010).","journal-title":"Circulation"},{"key":"1167_CR335","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1080\/13543776.2016.1211111","volume":"26","author":"CH George","year":"2016","unstructured":"George, C. H., Mitchell, A. N., Preece, R., Bannister, M. L. & Yousef, Z. Pleiotropic mechanisms of action of perhexiline in heart failure. Expert Opin. Ther. Pat. 26, 1049\u20131059 (2016).","journal-title":"Expert Opin. Ther. Pat."},{"key":"1167_CR336","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jacc.2024.03.387","volume":"83","author":"MS Maron","year":"2024","unstructured":"Maron, M. S. et al. Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 83, 2037\u20132048 (2024).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR337","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/s41569-024-01032-y","volume":"21","author":"GB Lim","year":"2024","unstructured":"Lim, G. B. Benefits of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy. Nat. Rev. Cardiol. 21, 357 (2024).","journal-title":"Nat. Rev. Cardiol."},{"key":"1167_CR338","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/eurheartj\/ehv597","volume":"37","author":"CM Gibson","year":"2016","unstructured":"Gibson, C. M. et al. EMBRACE STEMI study: a phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur. Heart J. 37, 1296\u20131303 (2016).","journal-title":"Eur. Heart J."},{"key":"1167_CR339","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002206","volume":"9","author":"HN Sabbah","year":"2016","unstructured":"Sabbah, H. N. et al. Chronic therapy with elamipretide (MTP-131), a novel mitochondria-targeting peptide, improves left ventricular and mitochondrial function in dogs with advanced heart failure. Circ. Heart Fail. 9, e002206 (2016).","journal-title":"Circ. Heart Fail."},{"key":"1167_CR340","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004389","volume":"10","author":"MA Daubert","year":"2017","unstructured":"Daubert, M. A. et al. Novel mitochondria-targeting peptide in heart failure treatment: a randomized, placebo-controlled trial of elamipretide. Circ. Heart Fail. 10, e004389 (2017).","journal-title":"Circ. Heart Fail."},{"key":"1167_CR341","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cardfail.2020.02.001","volume":"26","author":"J Butler","year":"2020","unstructured":"Butler, J. et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: the PROGRESS-HF phase 2 trial. J. Card. Fail. 26, 429\u2013437 (2020).","journal-title":"J. Card. Fail."},{"key":"1167_CR342","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jchf.2014.06.008","volume":"2","author":"SA Mortensen","year":"2014","unstructured":"Mortensen, S. A. et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2, 641\u2013649 (2014).","journal-title":"JACC Heart Fail."},{"key":"1167_CR343","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"1167_CR344","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1186\/s12872-024-04232-z","volume":"24","author":"J Xu","year":"2024","unstructured":"Xu, J. et al. Efficacy and safety of coenzyme Q10 in heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord. 24, 592 (2024).","journal-title":"BMC Cardiovasc. Disord."},{"key":"1167_CR345","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","volume":"397","author":"JA Spertus","year":"2021","unstructured":"Spertus, J. A. et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 397, 2467\u20132475 (2021).","journal-title":"Lancet"},{"key":"1167_CR346","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ejhf.3120","volume":"26","author":"E Bertero","year":"2024","unstructured":"Bertero, E. et al. Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population. Eur. J. Heart Fail. 26, 59\u201364 (2024).","journal-title":"Eur. J. Heart Fail."},{"key":"1167_CR347","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jacc.2021.04.065","volume":"78","author":"JR Teerlink","year":"2021","unstructured":"Teerlink, J. R. et al. Effect of ejection fraction on clinical outcomes in patients treated with omecamtiv mecarbil in GALACTIC-HF. J. Am. Coll. Cardiol. 78, 97\u2013108 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR348","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/ejhf.1933","volume":"22","author":"AA Voors","year":"2020","unstructured":"Voors, A. A. et al. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur. J. Heart Fail. 22, 1649\u20131658 (2020).","journal-title":"Eur. J. Heart Fail."},{"key":"1167_CR349","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT06736574 (2025)."},{"key":"1167_CR350","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00395-024-01067-9","volume":"119","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. Empagliflozin prevents heart failure through inhibition of the NHE1\u2013NO pathway, independent of SGLT2. Basic Res. Cardiol. 119, 751\u2013772 (2024).","journal-title":"Basic Res. Cardiol."},{"key":"1167_CR351","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","volume":"147","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2. Circulation 147, 276\u2013279 (2023).","journal-title":"Circulation"},{"key":"1167_CR352","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer, A. et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits. Diabetologia 60, 568\u2013573 (2017).","journal-title":"Diabetologia"},{"key":"1167_CR353","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman, L. et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 61, 722\u2013726 (2018).","journal-title":"Diabetologia"},{"key":"1167_CR354","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.121.057237","volume":"145","author":"B Hegyi","year":"2022","unstructured":"Hegyi, B. et al. Empagliflozin reverses late Na+ current enhancement and cardiomyocyte proarrhythmia in a translational murine model of heart failure with preserved ejection fraction. Circulation 145, 1029\u20131031 (2022).","journal-title":"Circulation"},{"key":"1167_CR355","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","volume":"5","author":"J Mustroph","year":"2018","unstructured":"Mustroph, J. et al. Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 5, 642\u2013648 (2018).","journal-title":"ESC Heart Fail."},{"key":"1167_CR356","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1161\/CIRCULATIONAHA.122.057364","volume":"146","author":"J Mustroph","year":"2022","unstructured":"Mustroph, J. et al. Empagliflozin inhibits cardiac late sodium current by Ca\/calmodulin-dependent kinase II. Circulation 146, 1259\u20131261 (2022).","journal-title":"Circulation"},{"key":"1167_CR357","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh, T. A. et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 44, 3627\u20133639 (2023).","journal-title":"Eur. Heart J."},{"key":"1167_CR358","doi-asserted-by":"publisher","unstructured":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018 (2024).","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"1167_CR359","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1167_CR360","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","volume":"31","author":"BA Borlaug","year":"2025","unstructured":"Borlaug, B. A. et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat. Med. 31, 544\u2013551 (2025).","journal-title":"Nat. Med."},{"key":"1167_CR361","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","volume":"85","author":"CM Kramer","year":"2025","unstructured":"Kramer, C. M. et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J. Am. Coll. Cardiol. 85, 699\u2013706 (2025).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR362","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai, M. Y. et al. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J. Am. Coll. Cardiol. 80, 95\u2013108 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1167_CR363","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","volume":"8","author":"Z Tian","year":"2023","unstructured":"Tian, Z. et al. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol. 8, 957\u2013965 (2023).","journal-title":"JAMA Cardiol."}],"container-title":["Nature Reviews Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01167-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01167-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01167-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T12:02:50Z","timestamp":1757937770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41569-025-01167-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":363,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1038\/s41569-025-01167-6","relation":{},"ISSN":["1759-5002","1759-5010"],"issn-type":[{"value":"1759-5002","type":"print"},{"value":"1759-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,22]]},"assertion":[{"value":"2 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.A. reports a research agreement with AstraZeneca. S.S. and M.A. hold a patent related to the cardiometabolic effects of nicotinamide and spermidine. M.P. reports a collaborative study with Boehringer Ingelheim. K.S.-B. has received grants from BionTech and Novartis and has received speaker\u2019s honoraria from Novartis. R.A.d.B. has had speaker engagements with and\/or received fees from and\/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche and Zoll; he has received travel support from Abbott and NovoNordisk, and his institution has received research grants and\/or fees from Abbott, Alnylam, AstraZeneca, Bristol Myers Squibb, NovoNordisk and Roche; V.S. has received research funding from Bristol Myers Squibb. C.M. is an advisory board member or speaker for Amgen, AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Edwards, Lilly, Novartis, NovoNordisk and Servier. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}